

# INDEX

## Volume Eleven—January through December 1977

### DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages 1 - 64
February	Pages 65 - 128
March	Pages 129 - 192
April	Pages 193 - 256
May	Pages 257 - 320
June	Pages 321 - 384

July	Pages 385 - 444
August	Pages 445 - 512
September	Pages 513 - 576
October	Pages 577 - 640
November	Pages 641 - 704
December	Pages 705 - 768

#### A

**Abish, Marvin** (author) letter, IV guidelines cost, 243

**Abortion**, use of 15(S)-15 methyl PFG<sub>2</sub>α to induce (ab) 63

**Absorption Rate Constant**, defined, 286

**Acetaminophen**, aspirin combination (letter) 245; charcoal, antidote for toxicity (letter) 368; dangers (letter) 59; dialysis, 412; in geriatric patients, 598; interference, theophylline assay (ab) 753; overdose, treatment with acetylcysteine (letter) 749; toxicity, 458, comments on Madan article (letter) 688, single plasma levels (letter) 426

**Acetazolamide**, weakness in paramyotonia congenita (ab) 377

**Acetic Acid**, for pressure sores, 154

**Acetylcysteine**, treatment for acetaminophen overdose (letter) 749

**1-α-Acetylmethadol (LAAM)**, plasma clearance (ab) 314

**Administration**, of IV solutions, methods, 352

**Adriamycin**, sensitivity, amphotericin B in human neoplasia, (ab) 253; streptozotocin-induced augmented toxicity (ab) 124

**Adverse Drug Reactions**  
 acetaminophen, dangers (letter) 59; toxicity (letter) 426, 458, acetylcysteine antidote, (letter) 749, charcoal antidote (letter) 368  
 acetazolamide, paramyotonia congenita (ab) 377  
 acetylcysteine, in treatment of acetaminophen overdose (letter) 749  
 amikacin, oxatotoxicity (ab) 61  
 aminophylline, toxicity, 12  
 amphetamine, shock after IV (ab) 563  
 antibiotics, pseudomembranous colitis, prophylactic use (ab) 123  
 anticonvulsants, liver biopsies in patients on long-term therapy (ab) 252  
 aspirin, hepatotoxicity (ab) 315, (letter) 749; renal function (ab) 377  
 atropine, bradycardia in preterm infants (ab) 61  
 barbiturate, intoxication, vertical gaze palsy (ab) 314  
 benzodiazepine, overdose (ab) 563  
 camphor, poisoning (letter) 110  
 carbenicillin, toxicity, 485  
 chlorambucil, and sterile cystitis (letter) 491  
 clindamycin, associated diarrhea, 520  
 clonazepam, drug fever (letter) 367  
 contraceptive, associated adenomas (ab) 315  
 cytotoxic agents, IV thrombophlebitic potential, 266  
 dantrolene associated hepatitis, 278  
 dialysis of drugs, 407  
 diazepam, allergy to (ab) 315  
 diethylstilbestrol, urogenital abnormalities (ab) 61  
 dinitrophenol, toxicity, 488  
 diphenhydramine, anticonvulsant osteomalacia (ab) 185  
 drugs, affecting the integumental system, 276  
 erythromycin estolate, induced hepatotoxicity, 22  
 flurazepam, toxicity in elderly (ab) 442  
 gentamicin, impaired renal function, 134; nephrotoxicity (letter) 428  
 hydrogen sulfide, intoxication (ab) 253  
 industry's obligation to clinical pharmacists, 740  
 lactulose, toxicity, 607  
 levodopa, induced anemia (ab) 503  
 meglumine iodipamide, hepatotoxicity (ab) 563  
 minocycline, reactions to, 26, (ab) 503  
 nitrofurantoin, pneumonitis, 854  
 operational identification of, 442  
 oxacillin, induced agranulocytosis, 420  
 pemoline (letter) 367  
 penicillin, induced coagulation disorder (ab) 123

pharmacists role in prevention of toxicity (ed) 176  
 phenacetin, induced sulfhemoglobinemia (ab) 123  
 phenytoin, induced nocturnal enuresis (letter) 492; induced systemic lupus erythematosus, 590; toxicity (letter) 57  
 procainamide, case study (letter) 425; hemodialysis for toxicity (ab) 124  
 propoxyphene, overdose treatment, 179  
 salicylate, unrecognized adult intoxication (ab) 252  
 sodium chloride, hypertonic, intra-amniotic injection (ab) 752; fatal ingestion of (ab) 628  
 spironolactone, induced gynecomastia, 70  
 tetracycline, drugs containing (letter) 180  
 tetracycline, hemorrhages, onycholysis (ab) 123  
 ticarcillin, toxicity, 485  
 to drug therapy, a sex difference, 402  
 treatment of drug overdose using liquid membranes (ab) 121  
 tricyclic antidepressants, arrhythmias (letter) 59; plasma levels: effects after overdose (ab) 314

**Advertising**, See **Drug Advertising**

**Agents**, Environmental, levels in breast milk, 219

**Agranulocytosis**, drug allergic, 420; oxacillin-induced, 420

**Albuterol**, beta-2-agonist, 526

**Alcohol**, levels in breast milk, 213; reaction with methyldopa (letter) 556

**Alexander, Michael A.** (author) book review, 435

**Alexander, Michael R.** (author) letter, corrections, beta-2 agonists, 689; (coauthor) The Beta-2 Agonist Bronchodilators, 526

**Algorithm**, for adverse drug reactions (ab) 442

**Allergic Drug Reactions**, oxacillin-induced agranulocytosis, 420

**Allopurinol**, interference, theophylline assay (ab) 753

**Alsop, Judith A.** (author) letter, pemoline adverse reactions, 367

**Amantadine**, levels in breast milk, 211

**American Board of Clinical Pharmacy**, meeting announcement (letter) 626

**Amerson, Ann B.** (coauthor) See **Baars, Ronald**, 610

**Amigen®**, trace elements, 466

**Amikacin**, compared with gentamicin (ab) 443; concentrations in kidneys, 564; kinetics during hemodialysis and peritoneal dialysis (ab) 378; ototoxicity (ab) 61

**Amino Acids**, total parenteral nutrition, 714

**Aminoglycosides**, dialysis, 410

**Aminophylline**, IV, dosage, 12; toxicity, 12; use, 30

**Aminosol®**, trace elements, 466

**Amitriptyline**, dialysis, 412; in geriatric patients, 597; levels in breast milk, 215

**Amoxicillin**, dialysis, 410; pharmacokinetics (ab) 378

**Amphetamine**, shock after IV (ab) 563

**Amphotericin B**, activity, stability (ab) 563; administration (letter) 368; dialysis, 410; induction of sensitivity to adriamycin, BCNU plus cyclophosphamide in human neoplasia (ab) 253; interaction with antioxidants (ab) 563; IV use, 30

**Ampicillin**, dialysis, 410; IV use, 30; pharmacokinetics from IV data (ab) 700; stability in minibags, 226, 542

**Anderson, Philip O.** (author) **Drugs and Breast Feeding - A Review**, 208

**Antibiotic Admixtures**, comparative stability in minibags and minibottles, unfrozen, 226, frozen, 542

**Antibiotics**, acute otitis media, 668; prophylactic use, pseudomembranous colitis (ab) 123; stability of admixtures in minibags, unfrozen, 226, frozen, 542

**Anticonvulsant**, induced systemic lupus erythematosus 590; therapy, liver biopsies in epileptics (ab) 252

**Antidepressants**, tricyclic (letter) 59

**Antimicrobial Therapy**, treatment of acute otitis media, 667

**Antipyrine**, metabolism with rifampicin (ab) 503

**Apparent Whole Blood, Serum or Plasma Clearance**, defined, 287

**Area Under The Curve**, defined, 286

**Arthritis**, flurbiprofen vs. ibuprofen, compared in (ab) 631

**Ascorbic Acid**, dialysis, 413; IV use, 30

**Aseptic Technique**, with protein hydrolysates, 714

**Aspirin**, acetaminophen combination (letter) 59, 245; blood fibrinolytic activity (ab) 377; co-deine in postpartum pain models (ab) 254; dialysis, 412; failure to antagonize spironolactone (ab) 253; gold induction in rheumatoid arthritis (ab) 501; hepatotoxicity (ab) 315, (letter) 749; levels in breast milk, 213; pharmacokinetics from IV data (ab) 700; renal function depression (ab) 377

**Atropine**, bradycardia in preterm infants (ab) 61; IV use, 30; levels in breast milk, 213

**Author Plagiarism**, comment on (letter) 244

**Authors**, See **Writing**

**Author's Guidelines**, for the preparation of DICP manuscripts, 3

**Ayotte, D. L.** (coauthor) See **Dinel, B. A.**, 226, 542

#### B

**Baars, Ronald** (coauthor) **Rapid Calculations for Emergency Practice**, 610

**Balsam Peru**, for pressure sores, 163

**Barbiturates**, adverse drug reaction (ab) 314; dialysis, 412; in geriatric patients, 597; interference, theophylline assay (ab) 753; levels in breast milk, 214; psychiatric views on prescribing (ab) 183

**Barletta, Michael A.** (author) letter, acetaminophen - a drug not without dangers, 59

**Barna, Peter** (author) letter, overdosage information in package inserts, 751

**Barreuther, Alan D.** (coauthor) letter, administration of amphotericin B, 368

**Bauman, Jerry L.** (coauthor) **Phenytoin Crystallization in Intravenous Fluids**, 646

**BCNU**, sensitivity reaction (ab) 253

**Bed Sore**, See **Pressure Sores**

**Behme, R. J.** (coauthor) See **Dinel, B. A.**, 226, 542

**Bendroflumethiazide**, levels in breast milk, 215

**Benya, Theodore J.** (author) book review, 630

**Benzodiazepines**, dialysis, 412; overdose (ab) 563

**Bergman, H. David** (author) **Incompatibilities in Large Volume Parenterals**, 345

**Bernardi, Vincent W.** (author) letter, CE for senior pharmacists, 108

**Beta-2 Agonist**, bronchodilators, 526; correction to Table 2 (letter) 689

**Bighley, Lyle** (coauthor) See **Hendles, Leslie**, 12

**Bioavailability**, defined, 286; digoxin, changes in cause intoxication (ab) 753, effect of sulfasalazine (ab) 253, in capsules (ab) 443; drug levels in breast milk, 208; milk inactivation of tetracycline (letter) 495; phenytoin products (ab) 700; prednisone (ab) 252; sodium valproate (ab) 754

**Biologic Availability**, defined, 286

**Biologic Half-Life**, defined, 286

**Biologic Equivalent**, bioequivalent, defined, 289

**Biopharmaceutics**, carbenicillin, 484; defined, 286; lactulose, 604; levels of drugs in breast milk, 208; progress in developing a standard terminology, 281; ticarcillin, 484

**Biopharmacy**, defined, 287

**Biotransformation**, defined, 287

**Birth Defects**, and prescribing (ab) 430

**Black, B. L.** (coauthor) See **Dinel, B. A.**, 226, 542

- Blacker, H. Martin (coauthor) See Rapp, Robert P. 462
- Bleomycin, in geriatric patients, 597
- Blondeaux, Anna M. (coauthor) letter, See Barreuther, Alan D., 368
- Books Received**
- Drug Fate and Metabolism: Methods and Techniques, (E. R. Garrett and J. L. Hirtz) 500
- Drug Metabolism, Chemical and Biochemical Aspects (B. Jesta and P. Jenner) 112
- Drug Metabolism Reviews, Volume 1 (F. J. DiCarlo) 435
- Drug Metabolism Reviews, Volume 2 (F. J. DiCarlo) 435
- The Effect of Disease States on Drug Pharmacokinetics (L. Z. Benet) 500
- The Fate of Drugs in the Organism, Volume 3 (J. Hirtz) 112
- Handbook of Experimental Pharmacology, Volume I, (Springer-Verlag) 112
- Handbook of Experimental Pharmacology, Volume II, (Springer-Verlag) 112
- Handbook of Injectable Drugs (L. A. Trisell) 500
- Interactions of Drugs of Abuse (E. S. Vesell and M. C. Braude) 500
- Lipid Chromatographic Analysis, Volume 3 (G. Marinetti) 112
- Self-Assessment of Current Knowledge in Pharmacy (F. Plakogiannis and A. Cutie) 112
- Synthetic Antidiarrheal Drugs (W. van Bever and H. Lal) 112
- Books Reviewed**
- Alcohol-Related Disabilities (G. Edwards, M. M. Gross, M. Keller, J. Moser and R. Room) 561
- The Anesthesiologist's Handbook (D. G. Catron) 629
- Catalog of Teratogenic Agents, 2nd Edition (T. H. Shepard) 372
- Clinical Pharmacy and Therapeutics (E. T. Herfindal and J. L. Hirschman) 373
- Clinical Pharmacy Sourcebook (W. A. Zellmer) 373
- Defined-Formula Diets for Medical Purposes (M. E. Shils) 692
- Drug Interactions (D. C. Grahame-Smith) 693
- Drugs and Central Synaptic Transmission (P. B. Bradley and B. N. Dhawan) 692
- Drugs Chemicals and Blood Dyscrasias (M. Swanson and R. Cook) 498
- Drug Therapy Reviews, Volume I (R. R. Miller and D. J. Greenblatt) 371
- Drug Treatment—Principles and Practice of Clinical Pharmacology and Therapeutics (G. S. Avery) 435
- Essentials of Pharmacology (J. A. Bevan) 433
- Evaluation of Dependence Liability and Dependence Potential of Drugs. Report of a WHO Scientific Group, 111
- Fat Emulsions in Parenteral Nutrition (H. C. Meng and D. W. Wilmore) 371
- Handbook: Interactions of Selected Drugs with Nutritional Status in Man (D. C. March) 561
- Handbook of Injectable Drugs (L. A. Trisell) 629
- The Historical Collection of the Pharmaceutical Society of Great Britain, 111
- International Nonproprietary Names (INN) for Pharmaceutical Substances, 1976 (World Health Organization) 630
- Marihuana Chemistry, Biochemistry and Cellular Effects (G. G. Nahas, W. D. M. Paton and J. E. Idanpaan-Heikkila) 500
- Microbial Drug Resistance (S. Mitsuhashi and H. Hashimoto) 373
- Prescription Proprietarys Guide, Eighth Issue, 1977-78-79, Australia and New Zealand (G. K. Treleaven) 561
- Progress in Toxicology: Volume 2 (G. Zbinden) 630
- Psychopharmacological Agents, Volume 4 (M. Gordon) 499
- Psychotherapeutic Drugs, Part II Applications (E. Usdin and J. S. Forrest) 693
- Repertorio Terapeutico (L. Marini) 498
- Selected Bibliography on Detection of Dependence-Producing Drugs in Body Fluids (T. L. Chrusciel & M. Chrusciel) 434
- Steroid Therapy (D. L. Azarnoff) 372
- Testing and Screening for Drugs of Abuse (G. G. DeAngelis) 112
- Therapeutics in Neurology (D. B. Calne) 434
- Toxicology: The Basic Science of Poisons (L. J. Casarett and J. Doull) 499
- Unit Dose and Drug Distribution Systems—1 (D. Tousignant) 488
- Yearbook of Medicine 1975 (D. E. Rogers, R. M. DesPrez, P. Heller, E. Braunwald, N. J. Greenberger, P. K. Bondy and F. H. Epstein) 433
- Bosso, John A. (author) letter, update on treatment of pneumocystis carinii pneumonia, 370; (coauthor) Acute Otitis Media, 665
- Bozian, Richard C. (coauthor) See Shearer, Cameron A., 465
- Bradberry, J. Chris (author) book review, 434
- Breast Feeding, excretion of drugs into breast milk, 208
- Bromide, levels in breast milk, 214
- Bromocriptine, levels in breast milk, 218; treatment of Parkinson's disease (ab) 184
- Bronchodilator, beta-2 agonists, 526; dyphylline (ed) 424
- Brooks, Geoffrey E. (coauthor) See Knapp, David A., 298
- Brooks, Gordon S. (author) letter, acetaminophen toxicity, 688
- <sup>14</sup>C-Bumetanide, pharmacokinetics (ab) 632
- Burleson, Ken (author) letter, acetylcysteine in the treatment of acetaminophen overdose, 749
- Burr, Gordon W. (author) letter, cost of two cephalosporins, 108
- C**
- Cacace, Larry G. (coauthor) Erythromycin Estolate Induced Hepatotoxicity: Report of a Case, 22
- Cacini, William (author) book review, 692
- Cady, William (coauthor) See Rapp, Robert P. 462
- Caiola, Stephen M. (coauthor) See Ludy, Judith Ann, 81
- Calcium, alternated with phosphorus infusions, effects on osteoporosis (ab) 62; IV, use, 30, nutrient requirements, 723; reduction in hypoparathyroid patients induced by furosemide (ab) 502
- Calculations, rapid for emergency practice, 610
- Calvert, Jon C. (coauthor) See Longe, R. Leon, 206, 270, 657, 743
- Campbell, R. Keith (coauthor) See Van Der Linde, Larry P., 30
- Campbell, William H. (author) Promised Land or Tower of Babel, 204
- Camphor, poisoning (letter) 110
- Cancer Therapy, See also Cytotoxic Agents, for metastatic breast cancer (ab) 185, with cytotoxic drugs (ab) 444
- Cannon, Marquette L. (coauthor) See LaFranco, Margherita M., 477
- Canrenone, solubility, 418
- Carbamazepine, levels in breast milk, 214
- Carbenicillin, dialysis, 410; IV use, 30; stability in minibags, 226, 542; ticarcillin, evaluation, 482
- Carbidopa, effect on sodium excretion (ab) 632
- Carbimazole, treatment for thyrotoxicosis (ab) 501
- Carbohydrates, with protein hydrolysates, 714
- Carbon dioxide, for pressure sores, 163
- Cardiac Emergency, rapid calculations for, 610
- Carmichael, Jan (coauthor) See Hendee, Leslie, 12
- Carry Over Effect, defined, 287
- Case Studies**
- acetaminophen toxicity, 458; active acromegaly (letter) 246; acute otitis media, 665; aspirin hepatotoxicity (ab) 315, (letter) 749
- chlorambucil cystitis (letter) 491; choice of IV solution, 549; clonazepam drug fever (letter) 367; copper deficiencies during total parenteral nutrition, 536
- dantrolene associated hepatitis, 278; diazepam, anaphylactic reaction to (ab) 315, in the treatment of tetanus (letter) 491; digitalis therapy and direct current shock, 73
- erythromycin estolate induced hepatotoxicity, 22; estrogen induced hyperlipemia in a male (letter) 556
- herbal drugs, intoxication with (ed) 686; Huntington's Chorea, 245
- Mediset™ induced overcompliance (letter) 687; methylodopa hepatitis (letter) 556
- nitrofurantoin pneumonia, 654
- oxacillin induced agranulocytosis, 420
- phenytoin, dosing in infants, 462; induced nocturnal enuresis (letter) 492; induced systemic lupus erythematosus, 590; metabolism stimulates loperamide (letter) 428
- physical assessment, integument, 276, of the ear, 657
- procainamide, adverse reaction (letter) 425; hemodialysis for toxicity (ab) 124
- sideroblastic anemia, 536; spironolactone induced gynecomastia, 70; squamous cell carcinoma (letter) 623
- zinc deficiencies during parenteral nutrition, 536
- Cassidy, Dennis (coauthor) See Hull, Robert Lee, 536
- Castor Oil, for pressure sores, 163
- Catania, Harriet (coauthor) See Jacobs, Richard S., 723
- Catellani, Joseph (author) letter, theophylline dosage calculation, 426
- Cavanaugh, Ann (coauthor) letter, See Tehrani, Jamshid B., 491
- Cawthorne, G. Kennedy (coauthor) letter, See Sartori, Helfried E., 556
- Cefadroxil, compared with cephalexin and cephadrine (ab) 378
- Cefamandole, effect of probenecid on serum levels (ab) 753; pharmacokinetics, clinical (ab) 185; during dialysis (ab) 62; with impaired renal function (ab) 62, (ab) 378
- Cefatrizine, pharmacology, maternal-fetal (ab) 698
- Cefazafur, kinetics compared to cephalothin and cefazolin (ab) 316
- Cefazolin, dialysis, 411; IV use, 30; pharmacokinetics, compared with cephalothin and cefazafur (ab) 316, from IV data (ab) 700; stability in minibags, 226, 542
- Cephalexin compared with cefadroxil and cephadrine (ab) 378; dialysis, 411; pharmacokinetics from IV data (ab) 700
- Cephaloridine, dialysis, 411
- Cephalosporins, comparative costs (letters) 108; dialysis, 411
- Cephalothin, dialysis, 411; IV use, 30; pharmacokinetics compared with cefazafur and cefazolin (ab) 316; stability in minibags, 226, 542
- Cephapirin, dialysis, 411
- Cephadrine compared with cefadroxil and cephalexin (ab) 378
- Cephulac®, drug evaluation data, 604
- Chain Drugstores, See Drugstore Chamberlain, Mary (coauthor) See Swenson, John P., 714
- Charcoal, and acetaminophen toxicity (letter) 368
- Chemotherapeutic Agents, dosage modifications in renal failure, 140
- Chemotherapy, and radiation therapy in acute leukemia (ab) 379; effect on EDCI (ab) 443; modified hydantoin derivatives and CNS tumors (ab) 752
- Child Abuse, physicians' knowledge (ab) 696
- China, health care in (ab) 430
- Chloral Hydrate, interaction with furosemide, 332; levels in breast milk, 214
- Chlorambucil, cystitis associated with (letter) 491
- Chloramphenicol, dialysis, 410; error in IV guidelines (letter) 307; IV use, 30; levels in breast milk, 211
- Chlordiazepoxide, dialysis, 412; in geriatric patients, 597; pharmacokinetics in healthy subjects (ab) 502
- Chloroform, levels in breast milk, 214
- Chloroquine, levels in breast milk, 210
- Chlorothiazide, levels in breast milk, 215
- Chlorpheniramine, pharmacokinetics (ab) 632
- Chlorpromazine, levels in breast milk, 215
- Chlorpropamide, metabolism, comment on Shen-Bressler article (letter) 624
- Cholestyramine, phenprocoumon, interaction (ab) 753
- Chrysler, Don R. (author) letter, marketed acetaminophen-aspirin combination, 245
- Chung, Edward K. (coauthor) See Deglin, Stuart, 76
- Cimetidine, drug evaluation data, 723
- Cis-diamminedichloroplatinum (II) anticancer drug (ab) 699
- Clearance, defined, 287
- Clement, William A. (author) letter, tricyclic antidepressants, 59
- Clindamycin, associated diarrhea, 520; dialysis, 411; in geriatric patients, 597; IV use, 30; levels in breast milk, 211; pharmacokinetics from IV data (ab) 700
- Clinical Clerkship, values of (letter) 180
- Clinical Pharmacist, comments on Dr. Clinical series (letters) 60, 109, 244, 305; prescribing, roles, 674; physical assessment, 200, (letter) 426; relationship with physicians, 674 (letter) 682
- Clinical Pharmacokinetics, defined, 288
- Clinical Pharmacology, defined, 287; ethical review (ab) 628
- Clinical Pharmacy See also Pharmacy Practice, Pharmacist's Roles
- defined, 288; degrees, doctorates, 681; number of (ed) 177; Statement of Council of Graduate Schools, 681; the family practice Pharm.D. (ed) 622; rebuttal to universal Pharm.D., 477; Dr. Clinical, appreciated (letter) 305; insight (letter) 60; is human (letter) 60; praised (letter) 370; pro (letter) 109; supported (letter) 109; too much flatus (letter) 244
- family practice, and the Report on the Study Commission on Pharmacy, 94; concept, roles and fees, 616; Pharm.D. (ed) 622
- levels of practice (letter) 109; literature filing system, 736
- meeting to define (letter) 626; misnomer, 98
- past, present and future, 674; pharmaceutical industry's obligation to, 740; promised land or Tower of Babel, comment on Mills Commission Report, 204
- reimbursement for services (ab) 247; roles,

- discussed, 674; physical assessment, 200, 270, 657; rebuttal to universal Pharm.D., 477
- Southwestern seminar (letter) 59; standards of practice (ed) 554
- Clinical Studies**, worldwide regulatory requirements on investigational drugs, 470
- Clinical Trials**, patient consent (ab) 182
- Clonazepam**, drug fever (letter) 367
- Clonidine**, resistance to effects (ab) 317
- Cloxacillin**, dialysis, 410; stability in minibags, 226, 542
- Coauthorship**, of scientific papers (letter) 558
- Cobalt**, trace element formula, 536
- Codeine**, aspirin in postpartum pain models (ab) 254; levels in breast milk, 213
- Colaizzi, J. L.** (coauthor) letter, see **Mathur, L. K.**, 368
- Colchicine**, familial Mediterranean fever (ab) 379
- Colestipol**, effect on digitoxin levels (ab) 125
- Colistimethate**, IV use, 30
- Colistin**, dialysis, 411
- Collagenase**, for pressure sores, 154
- Collier, W. A. L.** (author) Indexable Imprinting of Solid Dosage Forms, 170; (author) letter, systematic imprinting of solid dosage forms, 626
- Community Practice** See **Clinical Pharmacy, Pharmacy Practice, Pharmacist's Roles**
- Compartment**, defined, 288
- Compliance**, See **Patient Compliance**
- Computer Calculated Dosage**, kanamycin pharmacokinetics (ab) 633
- Congestive Heart Failure**, vasodilator therapy (ab) 254
- Consrue, Paul F.** (author) book review, 500
- Continuing Education**, calculations, rapid for emergency practice, 610; senior pharmacists (letter) 108
- Contraceptives**, Oral, adverse drug reaction (ab) 315; distribution (ab) 120
- Copper**, in hyperalimentation solutions, 466; replacement, sideroblastic anemia, tot.i par-enteral nutrition, 536
- Cornell, Joseph A.** (coauthor) letter, drugs containing tartrazine, 180
- Corrections**, beta-2 agonists bronchodilators, error in Table 2 (letter) 689; error in dialysis article (letter) 623; IV guidelines, amphotericin B alternate administration (letter) 368, chloramphenicol dosage error (letter) 307; digoxin alternate administration (letter) 306; heparin dosage error (letters) 306, oxytocin dosage clarification (letter) 243
- Corticosteroids**, levels in breast milk, 216
- Corticotropin**, IV use, 30
- Cosolvents**, use in solubilizing drugs for injection, 417
- Cost**, of cephalosporins (letters) 108; of health care (ab) 431
- Coumarin**, IV kinetics (ab) 316
- Counseling**, See **Patient Counseling**
- Covinsky, Joel O.** (author) book review, 372
- Criger, William H.** (coauthor) See **Davis, Robert E.**, 616
- Cyclophosphamide**, in acute leukemia (ab) 379; IV use, 30; levels in breast milk, 212; sensitivity reaction (ab) 253
- Cycloserine**, levels in breast milk, 211
- Cytosine Arabinoside**, kinetics (ab) 565
- Cytotoxic Agents**, See also **Cancer Therapy**
- cancer therapy (ab) 444; cis-diaminedichloroplatinum (II) (ab) 699; combination chemotherapy (ab) 253; ifosfamide evaluation (ab) 444; thrombophlebitic potential, IV, 266
- ## D
- Dahlin, Patricia A.** (coauthor) letter, see **Russell, Wayne L.**, 493
- Dantrolene**, hepatitis association, 278
- Daoud, David** (coauthor) letter, chlorambucil induced cystitis, 491
- Dasta, Joseph F.** (author) letter, theophylline therapy, 369
- Daunorubicin**, in acute leukemia (ab) 379
- Davies, K.** (coauthor) letter, see **Issa, Anne**, 492
- Davis, Robert E.** (coauthor) Pharmacy and Family Practice, 616
- DC Shock**, and digitalis (letter) 492
- Death**, psychotropic drugs (ab) 121
- Decker, Edward L.** (coauthor) letter, see **Lipman, Arthur G.**, 305
- Decubitus Ulcer** See **Pressure Sores**
- Definitions**, biopharmaceutic and pharmacokinetic terms, 286
- Deglin, Judith** (coauthor) See **Deglin, Stuart**, 76
- Deglin, Stuart** (coauthor) Direct Current Shock and Digitalis Therapy, 76; comment on article (letter) 492
- Degrees** See also **Pharm.D.**, honorary (letter) 493; number of (ed) 177; Pharm.D. in family practice, 616, (ed) 622; rebuttal to universal Pharm.D., 477; two professional degrees (letter) 106
- deHaen**, new product survey 1977 (ab) 694
- Deliganis, Sam G.** (coauthor) See **Wareham, Darryl V.**, 549
- Depression**, treatment with MAO inhibitors (ab) 631
- Devine, Ben J.** (coauthor) letters, American Board of Clinical Pharmacy meeting announcement, 626
- Dexamethasone**, IV use, 30
- Diabetics**, syringe devices for the visually impaired (letter) 623
- Diagnosis**, influence of training on (ab) 431
- Dialysis**, drug pharmacokinetics, 407; kinetics of amikacin (ab) 378
- Diazepam**, absorption with ethanol (ab) 314; allergy (ab) 315; dialysis, 412; in geriatric patients, 597; IV, in treatment of tetanus (letter) 491, precipitation in solutions (letter) 690, safety of infusion questioned (letter) 690, use, 30; levels in breast milk, 214; pharmacokinetics from IV data (ab) 700
- Diazoxide**, dialysis, 412; IV use, 30
- Dicloxacillin**, dialysis, 410
- Dicumarol**, levels in breast milk, 212
- Diet**, dinitrophenol, 488; in treatment of pressure sores, 164
- Diethylstilbestrol**, in the treatment of rape victims (ab) 182; urogenital tract abnormalities in sons of women treated with (ab) 61
- Diflunisal**, pharmacokinetics (ab) 698
- Digitalis**, effect on ventricular premature beats (ab) 502; therapy, calculation of antiarrhythmic doses of phenytoin (letter) 690, direct current shock, 76, (letter) 492
- Digitoxin**, dialysis, 411; levels, effect of colestipol (ab) 125; pharmacokinetics (ab) 699
- Digoxin**, bioavailability, effect of sulfasalazine (ab) 253, in capsules, (ab) 443; dialysis, 411; in geriatric patients, 597; IV use, 30; out-break of intoxication (ab) 753; pharmacokinetics from IV data (ab) 700
- Dihydrostreptomycin**, levels in breast milk, 212
- Dihydrotachysterol**, and breast feeding, 218
- Dinel, B. A.** (coauthor) Comparative Stability of Antibiotic Admixtures in Minibags and Minibottles, 226; (coauthor) Stability of Antibiotic Admixtures Frozen in Minibags, 542
- Dinitrophenol**, early therapeutic applications, 488
- Diphenhydramine**, pharmacokinetics from IV data (ab) 700
- Diphenylhydantoin** See **Phenytoin**
- Direct Current Shock**, digitalis therapy, 76
- Dispensing**, pharmacist or technician role, 95
- Disposition**, defined, 288
- Distribution**, defined, 288
- Distribution Rate Constant**, defined, 288
- Doctor of Pharmacy Degree**, See **Degrees and Pharm.D.**
- Dodds, Linda J.** (author) book review, 498, 499
- Dodge, Russell R.** (coauthor) letter, See **Barreuther, Alan D.**, 368
- Doele, Harry** (author) letter, IV guidelines, 306
- Dopamine**, IV use, 30
- Dose**, calculating theophylline, 151; modification of chemotherapeutic agents in renal failure, 140
- Dosage forms**, solid, imprinting of, 170, (letter) 626
- Doxycycline**, dialysis, 410; IV use, 30; pharmacokinetics (ab) 633
- Dr. Clinical**, appreciated (letter) 305; insight (letter) 60; is human (letter) 60; praised (letter) 379; pro (letter) 109; supported (letter) 109; too much flatus? (letter) 244
- Drug Abuse**, patient-pharmacist interaction, 81
- Drug Actions, Interactions and Reactions**, 61, 123, 184, 252, 314, 377, 442, 501, 563, 631, 698, 752
- Drug Administration**, guidelines for IV drugs (letter) 306
- Drug Advertising**, and drug use (ab) 496; government regulation on prescriptions, 338
- Drug Distribution Volume**, changes and pharmacokinetic implications (ab) 185
- Drug Evaluation Data**, cimetidine, 723; lactulose, 604; ticarcillin and carbenicillin, 482
- Drug Identification**, systematic imprinting of solid dosage forms 170, (letter) 626
- Drug Information**, bulletins (letter) 244; centers, 728; guide to Iowa Service (letter) 689; more wanted by pharmacists from drug industry, (letter) 493; pharmaceutical industry's obligation to clinical pharmacists, 740
- Drug Interaction**, warning system (ab) 627
- Drug Interactions**
- acetaminophen-charcoal (letter) 368
- adriamycin-streptozotocin (ab) 124
- alcohol-methyldopa (letter) 556
- amphotericin B-adriamycin, BCNU plus cyclophosphamide combination (ab) 253
- amphotericin B-antioxidants (ab) 563
- antioxidants-amphotericin B (ab) 563
- antipyrine-rifampin (ab) 503
- aspirin and increased fibrinolytic activity (ab) 377
- aspirin-codeine (ab) 254
- aspirin-spiroglactone (ab) 253
- cefamandole-probenecid (ab) 753
- charcoal-acetaminophen (letter) 368
- chloral hydrate-furosemide, 332
- cholestyramine-phenprocoumon (ab) 753
- codeine-aspirin (ab) 254
- combination chemotherapy-amphotericin B (ab) 253
- combination vasodilator therapy, in chronic congestive heart failure (ab) 254
- diazepam-ethanol (ab) 314
- digoxin-sulfasalazine (ab) 253
- ethanol-diazepam (ab) 314
- furosemide-chloral hydrate, 332
- hexobarbital-rifampin (ab) 503
- increased fibrinolytic activity-aspirin (ab) 377
- LAAM-methadone (ab) 314
- loxapine-phenytoin (letter) 428
- methadone-LAAM (ab) 314
- methyldopa-alcohol (letter) 556
- milk-tetracycline (letter) 495
- phenobarbital-warfarin (letter) 370
- phenprocoumon-cholestyramine (ab) 753
- phenytoin-loxapine (letter) 428
- probenecid-cefamandole (ab) 753
- rifampin-antipyrine (ab) 503
- rifampin-hexobarbital (ab) 503
- risks in long-term patients (ab) 497
- spironolactone-aspirin (ab) 253
- streptozotocin-adriamycin (ab) 124
- sulfasalazine-digoxin (ab) 253
- tetracycline-milk (letter) 495
- warfarin-phenobarbital (letter) 370
- Drug Overdose**, treatment (ab) 121
- Drug Prescribing**, barbiturates, psychiatrists views (ab) 183; birth defects (ab) 430; mal-prescribing of tetracycline (ab) 694; over-prescribing in Israel, 680; physician decision-making, 302; review in HMO (ab) 696
- Drug Product Selection**, 621
- Drugs**, affecting integument, 276; and breast feeding, 208; effects in geriatric patients, 597; excretion into breast milk, 208; guidelines for IV administration, 30; levels in breast milk, 210; pharmacokinetics of dialysis, 407; precipitation, solubilized due to injection or dilution, 417
- Drug Storage**, at home, 680
- Drugstore**, inappropriate use (ed) 686; influence with pharmaceutical educators, 100
- Drug Therapy**, in renal failure (ab) 565; patient compliance in acute otitis media, 669; pharmacist's role (ab) 120; sex variation, 398
- Drug Use**, Australia and the United States, 298; patterns in Israel, 678; television advertising's influence (ab) 496
- Duphulac**, drug evaluation data, 604
- Dyphylline**, "rational theophylline therapy" article contents questioned (letter) 624; "untheophylline" xanthine bronchodilator (ed) 424
- ## E
- Ear**, physical assessment of, 657
- Economic and Social Aspects of Drug Use**, See also **Health Care Sociology**, drug use in Australia and U.S., 298
- EDCI**, urinary excretion (ab) 443
- Editorials**
- Donald E. Francke, A New Meaning for Drugstore, 686; Parenteral Medication and the Nurse, 366; Patient Counseling by Health Practitioners, 490; Pharmacokinetic and Biopharmaceutic Terminology, 304; Physical Assessment and the Clinical Pharmacist, 242; The Pharmacist Prescriber, 105
- Edward A. Hartshorn, The Family Practice Pharm.D., 622
- Leslie Hendels (coauthor) Dyphylline: The "Untheophylline" Xanthine Bronchodilator, 424
- William A. Miller, Number of Degree Programs in Pharmaceutical Education, 177
- Gary M. Oederda, The Pharmacist - Dedicated to the Prevention of Drug Toxicity? 176
- Ronald B. Stewart, The Medicine Show Revisited, 686
- John G. Wagner, History of Pharmacokinetics, 747
- Miles Weinberger (coauthor) Dyphylline: The "Untheophylline" Xanthine Bronchodilator, 424
- Harvey A. K. Whitney, Jr., Standards of Practice, 554: The Pharmacy Technician Issue, 56
- Education and Training**, See **Pharmaceutical Education**
- Education, Pharmaceutical**, See **Pharmaceutical Education**
- Edwards, Drew** (coauthor) See **Swenson, John F.**, 714
- Electrolyte Replacement**, oral fluid therapy for diarrhea (ab) 559
- Electrolyte Therapy**, 549
- Elements, Trace**, in IV hyperalimentation solutions, 465
- Elimination**, defined, 289
- Elimination Rate Constant**, defined, 289
- Elliott Survey**, 204

**Emergency Treatment**, of drug overdose, using liquid membranes (ab) 121  
**Enflurane**, fluoride pharmacokinetics (ab) 125  
**Environmental Agents**, levels in breast milk, 219  
**Enzymes**, for pressure sores, 154  
**Epilepsy**, uncontrollable seizures in, 590  
**Ergonovine**, levels in breast milk, 218  
**Ergot Alkaloids**, levels in breast milk, 219; pharmacokinetics (ab) 633  
**Errors**, See **Corrections**  
**Erythromycin**, levels in breast milk, 212; estolate, induced hepatotoxicity, 22; gluceptate, stability in minibags, 256, 542  
**Estrogen**, induced hyperlipemia in a male (letter) 556; levels in breast milk, 216  
**Ethacrynic Acid**, IV use, 30  
**Ethanol**, effects on absorption of diazepam (ab) 314  
**Ethchlorvynol**, dialysis, 412  
**Ether**, levels in breast milk, 214  
**Ethical Review**, in the pharmaceutical industry (ab) 628  
**Ethics**, human experimentation with investigational drugs (ab) 497  
**Ethoximuside**, levels in breast milk, 214  
**Ethyl Biscoumacetate**, levels in breast milk  
**Ethynodiol**, solubility, 418  
**Excretion**, of drugs into breast milk, 20'

## F

**Fats**, with protein hydrolysates, 714  
**Federation Internationale Pharmaceutique**, 65th anniversary, 436; application for membership, 416; list of U.S. members, 436  
**Fee system**, pharmacy, 621  
**Flenfluramine**, actions of (ab) 564  
**Fenoprofen**, and gold induction in rheumatoid arthritis (ab) 501  
**Fibrinolysin-Desoxyribonuclease**, for pressure sores, 154  
**Fibrinolytic Activity**, increased after aspirin ingestion (ab) 377  
**Filing System**, clinical pharmacy literature, 736  
**Fink, Joseph L. III** (author) letter, pharm.D. Plagiarism, 180; (coauthor) letter, coauthorship of scientific papers, 558  
**"First Pass" Effect**, defined, 289  
**Fitzloff, John** (coauthor) See **Bauman, Jerry L.**, 646  
**Flatus**, Dr. Clinical is too much (letter) 244  
**Flour Plan**, model for family practice, 618  
**Flucytosine**, dialysis, 410  
**Flufenamic Acid**, levels in breast milk, 213  
**Fluid Therapy**, See also **Intravenous Parenteral Solutions**, fluid and electrolyte therapy, 549; oral, for diarrhea (ab) 559  
**Fluorouracil**, IV use, 30  
**Flurazepam**, dialysis, 412; in geriatric patients, 597; toxicity in elderly (ab) 442  
**Flurbiprofen**, vs. ibuprofen, compared in arthritis (ab) 631  
**Folic Acid**, dialysis, 413  
**Folkerts, Lorraine N.** (coauthor) letter, See **Gray, Roland**, 367  
**Fong, William L.** (coauthor) letter, aspirin hepatotoxicity, a case report, 750  
**Foods**, levels in breast milk, 217  
**Formularies**, 621  
**Formulary**, control of prescribing (ab) 696  
**Formulation**, of IV solutions, 352  
**Forni, Peter J.** (coauthor) letter, See **Devine, Ben J.**, 626  
**FO-TI-TING**, misuse of (ed) 686  
**Fox, Nathan** (coauthor) letter, See **Daoud, David**, 491  
**Franeck, Donald E.** (ed) A New Meaning for Drugstore, 686; (ed) Parenteral Medication and the Nurse, the Pharmacist and the Physician, 366; (ed) Patient Counseling by Health Practitioners, 490; (ed) Pharmacokinetic and Biopharmaceutic Terminology, 304; (ed) Physical Assessment and the Clinical Pharmacist, 242; (ed) The Pharmacist Prescriber, 105  
**FreAmine II®**, trace elements, 466  
**Furosemide**, dialysis, 412; hypoparathyroid patients with calcium reduction (ab) 502; interaction with chloral hydrate, 332; IV use, 30

## G

**Gagnon, Jean Paul** (coauthor) See **Ludy, Judith Ann**, 81  
**Garner, Deway D.** (coauthor) See **Larson, Lon N.**, 338  
**Gebhardt, Peggy** (author) letter, syringe devices for visually impaired diabetics, 623  
**Gecewich, Mike** (author) letter, pro Dr. Clinical, 109  
**Gee, Joseph C.** (coauthor) See **Hood, Jerry C.**, 362  
**Gelfoam**, for pressure sores, 154  
**Gentamicin**, compared with amikacin (ab) 443; concentrations in kidneys (ab) 564; dialysis, 410; impaired renal function, 134; in geriatric patients, 597; IV use, 30; nephrotox-

icity (letter) 428; stability in minibags, 226, 542  
**George, John** (coauthor) See **Sather, Mike R.**, 154  
**Gerbino, Philip P.** (coauthor) letter, See **Fink, Joseph L. III**, 558  
**Geriatric Patients**, aminophylline dosage, 12; drug effects in, 597  
**Gildon, Andrew M.** (coauthor) See **Cacace, Larry G.**, 22  
**Glucocorticoids**, dialysis, 413  
**Glucose-Electrolyte Solution**, oral fluid therapy for diarrhea (ab) 559  
**Glutethimide**, dialysis, 412; levels in breast milk, 214  
**Glyceryl Trinitrate**, pharmacokinetics (ab) 632  
**Goetsch, Donald W.** (author) letter, Dr. Clinical is human, 60  
**Gold**, induction and fenoprofen, aspirin, in rheumatoid arthritis (ab) 501; levels in breast milk, 219  
**Goldstein, George S.** (author) letter, tartrazine, 492  
**Goodman, Maxine E.** (author) letter, Dr. Clinical praised, 370  
**Gray, David R.** (author) letter, physical assessment by the pharmacist endorsed, 623  
**Gray, Roland** (coauthor) letter, drug fever due to clonazepam, 367  
**Greenlaw, Cal W.** (author) letter, gentamicin nephrotoxicity, 428; (author) letter, laetrile and the profession of pharmacy, 427; (author) spironolactone induced gynecomastia, 70; (author) letter, treatment of propoxyphene overdose, 179  
**Grill, Frank J.** (coauthor) Clinical Experience With Minocycline Reactions, 26  
**Griseofulvin**, pharmacokinetics from IV data (ab) 700  
**Grossman, Joshua Bernard** (author) letter, pharmacist aids diagnosis, 246; (author) letter, physical assessment by the pharmacist encouraged, 623  
**Grotting, Michael A.** (author) letter, drug newsletters wanted, 688  
**Guernsey, Brock** (coauthor) See **Alexander, Michael R.**, 526  
**Guidelines**, author, DICP manuscripts, 3; for IV drugs, 30; (letter) 306; large volume parenteral solutions, 345; recommended for handling frozen minibags, 542  
**Gurwich, Ernest L.** (coauthor) letter, See **Slama, Philip J.**, 750  
**Gynecomastia**, spironolactone induced, 70

## H

**Haase, Pamela S.** (author) letter, pseudotumor cerebri, 108  
**Haines, Bernard A., Jr.** (author) Worldwide Regulatory Requirements and Their Effects on the Clinical Study and Transport of Investigational New Drugs, 470  
**Halbert, Michael R.** (coauthor) Drug Information Centers: Lack of Generic Equivalence, 728  
**Half-Life** See also **Biologic Half-Life**  
**Hall, Clifford A.** (coauthor) See **Simonson, William**, 654  
**Hambuchen, Mike** (author) letter, cost of cephalosporins, 108  
**Hans, Robert** (author) letter, chloramphenicol sodium succinate (Chloromycetin) dosage error in IV guidelines, 307  
**Hanson, Russell F.** (coauthor) See **Lundin, Sharon R.**, 278  
**Hansten, Philip D.** (author) book review, 372, 561  
**Hartshorn, Edward A.** (ed) The Family Practice Pharm.D., 622  
**Health Care**, costs (ab) 431; in China (ab) 430  
**Health Care Sociology**  
 administration of blood products, nurses' practice and knowledge (ab) 183  
 barbiturate prescribing: psychiatrists' views (ab) 183  
 characteristics of heavy users of outpatient prescription drugs (ab) 120  
 Child Abuse - Physician's Knowledge (ab) 696  
 China invaded by U.S. medical students (ab) 430  
 clinical pharmacology, ethical review (ab) 628  
 death, medical staff/patient (ab) 182  
 dentist-pharmacist relationship in pain control (ab) 249  
 diethylstilbestrol and treatment of rape victims (ab) 182  
 drug prescribing and birth defects (ab) 430  
 drug prescribing, review in HMO (ab) 696  
 ethics of human experimentation (ab) 497  
 fatal ingestion of table salt (ab) 628  
 goal implementation and outcome in medical schools (ab) 247  
 health economics and preventive care (ab) 431  
 home-based respiratory rehabilitation (ab) 183

hypnosis, aid to stopping smoking (ab) 183  
 kidney transplants in patients over 50 (ab) 247  
 malprescribing of liquid tetracycline preparations (ab) 694  
 new drugs introduced in 1977 (ab) 694  
 nurse, family planning (ab) 121  
 oral contraceptive distribution (ab) 120  
 oral fluid therapy for diarrhea (ab) 559  
 patient's acceptance of physician's assistants (ab) 432  
 patient volunteers in clinical trial (ab) 182  
 pharmaceutical education, cost of clinical education (ab) 627  
 pharmacist's role in drug therapy (ab) 120  
 pharmacy's image (ab) 121  
 primary care, physician management of patients (ab) 627  
 psychotropic drugs, deaths, suicide, non-suicide (ab) 121  
 reimbursement for clinical pharmacy services (ab) 247  
 risk of medicinal interaction in long-term patients (ab) 497  
 social structure in a group of scientists: a test of the "invisible college" hypothesis (ab) 248  
 susceptibility of woman athletes to injury (ab) 249  
 television advertising and drug use (ab) 496  
 training and physician utilization behavior (ab) 431  
 transcendental meditation in patients with chronic obstructive pulmonary disease (ab) 182  
 treatment of drug overdose (ab) 121  
 warfarin, in breast milk (ab) 694  
 warning system for drug interaction (ab) 627  
 who responds to sugar pills (ab) 249  
**Hemodialysis**, for procainamide toxicity (ab) 124  
**Hendeles, Leslie** (author) book review, 373; (coauthor) (ed) *Dynpylline: The "Untheophylline"* Xanthine Bronchodilator, 424; (coauthor) *Frequent Toxicity from IV Aminophylline Infusions in Critically Ill Patients*, 12; (coauthor) See **Alexander, Michael R.**, 526  
**Henney, Jane E.** (coauthor) *Thrombophlebitic Potential of Intravenous Cytotoxic Agents*, 266  
**Heparin**, in geriatric patients, 597; IV use, 30  
**Hepatotoxicity** See **Liver Function**  
**Hepler, Charles D.** (coauthor) See **Hendeles, Leslie**, 12  
**Herbal Drugs**, misuse (ed) 686  
**Heroin**, levels in breast milk, 213  
**Hexobarbital**, metabolism with rifampicin (ab) 503  
**Hildebrandt, William K.** (author) letter, phenytoin-induced nocturnal enuresis, 492  
**Hirschman, Joseph L.** (author) letter, Dr. Clinical supported, 109  
**History**, dinitrophenol, 488  
**Hoffmann, Richard P.** (coauthor) *Impaired Renal Function Secondary to Gentamicin*, 134  
**Hood, Jerry C.** (coauthor) *Characteristics of Outpatient Medications and Implications with Hospitalizations*, 362  
**Horn, John R.** (author) book reviews, 433  
**Horton, Thomas E.** (coauthor) letter, intravenous oxytocin infusion, 243  
**Hospital Pharmacy**, standards of practice (ed) 554  
**Howell, William S.** (coauthor) See **Pevonka, M. Peter**, 332  
**Huff, Marvin R.** (author) letter, value of clinical clerkship, 180  
**Hull, Robert Lee** (coauthor) letter, phenytoin toxicity due to severe liver disease, 57; (coauthor) *Trace Element Deficiencies During Total Parenteral Nutrition - A Case of Sideroblastic Anemia Due to Inadequate Copper Replacement*, 536  
**Huntington's Chorea**, case study (letter) 245  
**Hy, Ronn** (coauthor) See **Larson, Lon N.**, 338  
**Hydantoin Derivatives**, use in CNS chemotherapy (ab) 752  
**Hydralazine**, pharmacokinetics of elimination (ab) 503  
**Hydrochlorothiazide**, in essential hypertension (ab) 501  
**Hydrocodone** (letter) package information inconsistent, 751  
**Hydrocortisone**, IV use, 30  
**Hydroflumethiazide**, pharmacokinetics (ab) 502  
**Hydrogen Sulfide**, intoxication (ab) 253  
**Hydroxyzine**, interference, theophylline assay (ab) 753  
**Hyperalimentation Solutions**, See **Parenteral Nutrition**  
**Hypnosis**, group vs. individual treatment (ab) 183  
**Hypoglycemics**, Oral, dialysis, 413

## I

**Iatrogenic Diseases**, See **Adverse Drug Reactions**, **Individual Drug Names**

**Ibuprofen**, vs. flurbiprofen compared in arthritis (ab) 631  
**Ice Packs**, for pressure sores, 163  
**Identification**, of adverse drug reactions (ab) 443; of solid dosage forms, 170  
**Ifosfamide**, evaluation (ab) 444  
**Imipramine**, dialysis, 412; in geriatric patients, 597; levels in breast milk, 215  
**IMPRES**, indexable imprinting of solid dosage forms, 170, (letter) 626  
**Incompatibilities**, in large volume parenterals, 345  
**Infants**, excretion of drugs into breast milk, 208; phenytoin dosing, 462  
**Information**, drug bulletins (letter) 244  
**Insulin**, for pressure sores, 163; IV use, 30; use with protein hydrolysates, 714  
**Integument System**, physical assessment, 270; post-test for physical assessment series, 743  
**International Pharmaceutical Federation**, See **Federation Internationale Pharmaceutique**  
**International Vocabulary**, of Biopharmaceutic and pharmacokinetic terms, 291  
**Intravenous**, See also **Parenteral Solutions**, administration of drugs, guidelines, 30; aminophylline toxicity, 12; cytotoxic agents, thrombophlebotic potential, 226; diazepam in tetanus (letter) 491; fluids, phenytoin crystallization, 646; guidelines (letter) 306, reprint cost (letter) 243; trace elements in hyperalimentation solutions, 465  
**Invasion**, defined, 289  
**Investigational Drug Information**, ethics in human experimentation defined (ab) 497  
**Investigational Drugs**, worldwide regulatory requirements, 470  
**Iodide**, sodium, levels in breast milk, 219; trace element formula, 536  
**Iopanoic Acid**, levels in breast milk, 219  
**Iowa Drug Information Service**, self-instructional guide (letter) 689  
**Ipratropium Bromide**, anticholinergic bronchodilator (ab) 316  
**Iron**, dextran, IV use, 30; in geriatric patients, 597; use with protein hydrolysate, 714  
**Isoetharine**, beta-2 agonist, 526  
**Isoniazid**, dialysis, 411; levels in breast milk, 212; pharmacokinetics of metabolism (ab) 164  
**Isopterenolol**, IV use, 30  
**Isoxide dinitrate**, plasma concentrations (ab) 379, (ab) 699  
**Issa, Anne**, (coauthor) letter, DC shock and digitalis, 492  
**IV fluids**, See **Intravenous, Parenteral Solutions**  
**Ivey, Marianne F.** (coauthor) See **Swenson, John P.**, 714

# J

**Jackman, Jerald R.** (coauthor) See **Bosso, John A.**, 665  
**Jacobs, Richard S.** (coauthor) Cimetidine Evaluation, 723  
**Jaffe, J. M.** (coauthor) letter, See **Mathur, L. K.**, 368  
**Jarrah, Azmi S.** (coauthor) See **Grill, Frank J.**, 26  
**Jenicsek, John A.** (author) book review, 629  
**Jones, Mark E.** (author) book review, 373  
**Jones, William N.** (author) letter, professional degrees, 107  
**Joyner, Pamela U.** (coauthor) See **Merritt, Gerald J.**, 458

# K

**Kanamycin**, dialysis, 410; in geriatric patients, 597; IV use, 30; levels in breast milk, 212; pharmacokinetics, computer-calculated (ab) 633  
**Kansas**, University of Missouri students in China (ab) 430  
**Karaya**, for pressure sores, 154  
**Katz, Seymour** (coauthor) The Pharmaceutical Industry's Obligation to Clinical Pharmacists, 740  
**Kaul, Alan F.** (coauthor) letter, See **Horton, Thomas E.**, 243  
**Kehrer, James P.** (author) letter, Dr. Clinical appreciated, 305  
**Kelly, William N.** (coauthor) See **Halbert, Michael R.**, 728  
**Kerkhof, Kent** (author) letter, trace element concentration in Travasol® injections, 690  
**Kern, Jack W.** (coauthor) Rational Theophylline Therapy. A Review of the Literature with a Guide to Pharmacokinetics and Dosage Calculation, 144, addendum to article (letter) 305; comments on article (letters) 369, 426, author's reply (letter) 494; rational theophylline therapy article contents questioned (letter) 625, author's reply (letter) 625  
**Khalidi, Nabil**, (author) book review, 371  
**Kidney Function**  
 acetaminophen (letter) 59  
 amikacin, nephrotoxicity (ab) 443  
 aspirin-induced depression (ab) 377  
 carbenicillin, dosage and, 485

cefamandole, pharmacokinetics (ab) 378  
 dialysis of drugs, 407  
 drug therapy guidelines (ab) 565  
 gentamicin, nephrotoxicity, 134, (letter) 428, (ab) 444  
 impaired by anticancer drugs, 140  
 kidney transplant in patients over 50 (ab) 247  
 metolazone in renal failure (ab) 752  
 ticarcillin, dosage and, 485  
 tobramycin, fetal (ab) 753  
**Kitenos, Jack G.** (author) book review, 498  
**Knapp, David A.** (coauthor) Drug Use in Australia and the United States as Reflections of Legislation and Social Attitudes, 298; (author) letter, replying to comments relative to two degrees, 107  
**Knapp, Deanne E.** (coauthor) See **Knapp, David A.**, 298  
**Kramer, Warren** (author) letter, pharmacy administration as a level of pharmacy practice, 179

# L

**LAAM**, plasma clearance (ab) 314  
**Labeling of Medication**, poor labeling associated with increased mortality, 362  
**Lactulose**, drug evaluation data, 604  
**Laetrile**, and the profession of pharmacy (letter) 427  
**LaFranco, Margherita M.** (coauthor) Point/Counterpoint, 477  
**Lamy, Peter P.** (coauthor) See **Proksch, Richard A.**, 398  
**Larson, Lon N.** (coauthor) Government Regulation and the Believability of Prescription Drug Advertising: An Application of Attribution Theory and Test of Symbolic Impact, 338  
**Laxatives**, levels in breast milk, 215  
**Lead**, levels in breast milk, 220  
**Lee, J. Douglas** (coauthor) See **Stewart, Ronald B.**, 520  
**Legal**, worldwide requirements for investigational drugs, 470  
**LeGrady, Dan** (author) letter, volume of distribution, theophylline, 494  
**Lepik, Anne** (coauthor) letter, adverse reaction to procainamide, 425  
**Letters to the Editor**  
 acetaminophen, a drug not without dangers, 59; acetylcysteine use in overdose, 749; charcoal use in overdose, 368; toxicity and single plasma levels, 428, reply, 688; U.S. marketed combination with aspirin, 245  
 alcohol-methylidopa reaction, 556  
 American Board of Clinical Pharmacy meeting announcement, 626  
 amphotericin B, IV administration, 368  
 aspirin hepatotoxicity: a case report, 749  
 beta-2 agonists - correction, 689  
 camphor poisoning, 110  
 CE for senior pharmacists, 108  
 chlorambucil, sterile cystitis associated with, 491  
 chlorpropamide metabolism, 624  
 clinical clerkship, value of, 180  
 clonazepam, drug fever due to, 367  
 coauthorship of scientific papers, 558  
 cost of, cephalosporins, 108; two cephalosporins, 108  
 dialysis of drugs, error in article, 623  
 diazepam infusion, in the treatment of tetanus, 491; safety of questioned, 690  
 digitalis, and DC shock, 492  
 Dr. Clinical, appreciated, 305; insight, 60; is human, 60; praised, 370; pro, 109; supported, 109; too much flatus? 244  
 drug, information bulletins, 244; newsletters wanted, 688  
 education, films, 688  
 effects of pharmacist consultation on patient compliance, 749  
 epidemiological evaluation of drugs, symposium on, 181  
 estrogen-induced hyperlipemia in a male, 556  
 estrogen-induced hyperlipemia in a male, 556  
 family pharmacist, 369, kudos to, 305  
 gentamicin nephrotoxicity, 428  
 guidelines for the IV administration of drugs, 306; dosage error, chloramphenicol sodium succinate (chloromycetin) 307, heparin, 306; reprint cost, 243  
 honorary doctorate degree, 493  
 Huntington's Chorea, 245  
 industry's interest, 493  
 Laetrile and the profession of pharmacy, 427  
 levels of pharmacy practice, 109, 557; pharmacy administration as, 179, 243  
 Mediset™ -induced over-compliance, 687  
 milk inactivation of tetracycline, 495  
 Northwest management seminar, 244  
 oxytocin infusion, intravenous, 243  
 package inserts, inconsistencies in, 751

pharmacist aids diagnosis, 246  
 pharmacy revolution needed, 58  
 phenytoin, an alternative method for the calculation of antiarrhythmic doses in digitalized patients, 690; induced nocturnal enuresis, 492; metabolism stimulated by loxapine, 428; toxicity due to severe liver disease, 57  
 physical assessment and the clinical pharmacist, comments, 426; encouraged, 623; endorsed, 623  
 plagiarism, author, 244; Pharm.D., 180  
 pregnancy testing, 555  
 procainamide, adverse reaction to, 425  
 professional degrees, two? comment on article, 106; author replies, 107  
 propoxyphene overdose, treatment, 179  
 pseudotumor cerebri, 108  
 self-instructional guide to the Iowa Drug Information Service, 689  
 small-volume unit dose packaging, 109  
 solid dosage forms, systematic imprinting, 626  
 southwestern clinical pharmacy seminar, 59  
 syringe devices for visually impaired diabetics, 623  
 tartrazine, drugs containing, 180, 492  
 theophylline therapy, review, 144; addendum to, 305; comments on, 369; author replies, 494; article questioned, 624; author's reply, 624; dosage calculation, 426; volume of distribution, 494  
 trace element concentration in Travasol® injections, 690  
 treatment of pneumocystis carinii pneumonia, update, 370  
 tricyclic antidepressants, continued, 59  
 TSHC annual seminar, 495  
 warfarin and phenobarbital interaction, 370  
**Levaterenolol**, IV use, 30  
**Levels of pharmacy practice**, opinions (letters) 109, 557; administration as (letters) 179, 243  
**Levine, Richard J.** (author) Accountability and Responsiveness - Use of Minicharts, 92  
**Levodopa**, in geriatric patients, 597; therapy, hemolytic anemia (ab) 503  
**Lidocaine**, IV use, 30  
**Lincomycin**, dialysis, 411; IV use, 30; levels in breast milk, 212  
**Lipman, Arthur C.** (coauthor) See **Kern, Jack W.**, 144; (coauthor) letter, addendum: rational theophylline therapy, 305; (coauthor) letter, authors' reply to criticism of theophylline therapy article, 625  
**Literature**, 111, 371, 433, 498, 561, 629, 692; filing system for the clinical pharmacist, 736  
**Lithium**, dialysis, 412; in geriatric patients, 597; levels in breast milk, 215  
**Liver Function**  
 acetaminophen, toxicity, 458; (letter) 59; (letter) 426  
 alcohol-methylidopa reaction (letter) 556  
 antiepileptic treatment, long-term (ab) 252  
 aspirin, hepatotoxicity (ab) 315; (letter) 749  
 contraceptives, cell adenomas associated with (ab) 315  
 dantrolene, associated hepatitis, 278  
 erythromycin, induced hepatotoxicity, 22  
 meglumine iodipamide, hepatotoxicity (ab) 563  
 phenytoin, toxicity (letter) 57  
 streptozotocin and adriamycin, in combination (ab) 124  
**Longe, R. Leon** (coauthor) Physical Assessment and the Clinical Pharmacist, 200, comment on article (letter) 426; (coauthor) Physical Assessment of the Ear, 657; (coauthor) Physical Assessment of the Integumental System, 270; (coauthor) Physical Assessment of the Integumental System Post-Test, 743  
**Lopez, Frank** (coauthor) letter, See **Devine, Ben J.**, 626  
**Loxapine**, stimulates phenytoin metabolism (letter) 428  
**Ludy, Judith Ann** (coauthor) The Patient-Pharmacist Interaction in Two Ambulatory Settings, 81  
**Lundin, Sharon R.** (coauthor) Dantrolene-Associated Hepatitis, 278  
**Lupus Erythematosus**, See **Systemic Lupus Erythematosus**

# M

**Madan, Parshotam L.** (author) letter, acetaminophen toxicity, 426  
**Magnesium**, IV, nutrient requirements, 723, use, 30  
**Mandelic Acid**, levels in breast milk, 211  
**Manganese**, in hyperalimentation solutions, 466; trace element formula, 536  
**Mannitol**, IV use, 30  
**MAO Inhibitors**, use of in depression (ab) 631  
**Marks, Ronald G.** (coauthor) See **Pevonka, M. Peter**, 332  
**Martin, David J.** (author) letter, Huntington's Chorea, 245  
**Martin, Henry, Jr.** (coauthor) See **Davis, Robert E.**, 616

Mathematics, rapid calculations for emergency practice, 610  
 Massoud, Neil (coauthor) letter, See Lepik, Anne, 425  
 Mathur, L. K. (coauthor) letter, charcoal and acetaminophen toxicity, 368  
 Matthews, Patricia A. (coauthor) letter, See Ryan, Gae M., 428  
 Matzke, Gary M. (author) letter, an alternative method for the calculation of antiarrhythmic doses of phenytoin in digitalized patients, 690  
 McLean, William M. (author) letter, safety of diazepam infusion questioned, 690  
 McLeod, Don C. (ed) drug evaluation data, 482, 605, 723; (coauthor) A Literature Filing System for the Clinical Pharmacist, 736  
 Medication Errors, criteria for determining, 83  
 Medications, labeling of, and mortality, 362; outpatient & implications with hospitalizations, 362  
 Mediset<sup>TM</sup>, induced overcompliance (letter) 687  
 Mefenamic Acid, levels in breast milk, 213  
 Meglumine Iodipamide, hepatotoxicity (ab) 563  
 Mehl, Bernard (author) letter, pharmacy administration as a level of pharmacy practice, 179  
 Melikian, David M. (author) letter, chlorpropamide metabolism, comment on Shen-Bressler article, 624  
 Meperidine, in geriatric patients, 597  
 Meprobamate, levels in breast milk, 214  
 Merbromin, for pressure sores, 154  
 Merritt, Gerald J. (coauthor) Acetaminophen Toxicity, 458; (coauthor) letter, See Selle, Robert I. Jr., 623  
 Metals, trace, in hyperalimentation solutions, 465  
 Metaprotrenolol, beta-2 agonist, 526  
 Methadone, levels in breast milk, 213  
 Methenamine, levels in breast milk, 211  
 Methicillin, dialysis, 410; IV use, 30  
 Methotrexate, IV use, 30; levels in breast milk, 213; psoriasis therapy (ab) 444  
 Methylodopa, dialysis, 412; IV use, 30; reaction with alcohol (letter) 556  
 Methylprednisolone, IV use, 30  
 Methypyrrolon, dialysis, 412  
 Metoclopramide, and placebo compared (ab) 443; in gastroesophageal reflux (ab) 443; levels in breast milk, 215  
 Metolazone, in renal failure (ab) 752  
 Metronidazole, levels in breast milk, 212  
 Milk, excretion of drugs into breast milk, 208; inactivation of tetracycline (letter) 495  
 Miller, Douglas E. (coauthor) See Halbert, Michael R., 728  
 Miller, William A. (ed) Number of Degree Programs in Pharmaceutical Education, 177  
 Mills Report See Report of Study Commission on Pharmacy, 204  
 Minerals, levels in breast milk, 217; trace in parenteral nutrition, 536  
 Minibags, stability of, antibiotics in, 226; frozen antibiotics in, 542  
 Minibottles, stability of antibiotics in, 226  
 Minocycline, adverse drug reactions (ab) 503; diagnosis and treatment (ab) 62; IV use, 30; reactions to, 26  
 Minoxidil, in malignant hypertension (ab) 379  
 Monitoring, See also Patient Monitoring, Patient Profiles, fluid and electrolyte therapy, 549; related to physical assessment, 200; drug effects, integumental system, 276  
 Monoamine Oxidase Inhibitors, use of in depression (ab) 631  
 Mood, Darlene W. (coauthor) See Hoffman, Richard P., 134  
 Morita, Yoshikazu (coauthor) See Shinn, Arthur F., 140  
 Morphine, in geriatric patients, 597; levels in breast milk, 213  
 Muggia, Franco M. (coauthor) See Henney, Jane E., 266  
 Mugwort Tea, misuse of (ed) 686  
 Multiple Sclerosis, a review (ab) 565  
 Murphy, John E. (coauthor) See Hood, Jerry C., 362  
 Murray, Gordon A. (author) letter, alcohol-methylodopa reaction, 556

## N

Nafcillin, IV use, 30  
 Nalidixic Acid, levels in breast milk, 211  
 Naloxone, drug actions (ab) 252; IV in schizophrenia (ab) 699  
 Neomycin, dialysis, 410  
 Nephrotoxicity See Kidney Function  
 New Drugs, introduced in 1977 (ab) 694; worldwide regulatory requirements on study of, 470  
 Newsletters, See also Drug Information Bulletins, wanted (letter) 688  
 Nice, Frank J. (author) letter, the family pharmacist, 305  
 Nicotine, levels in breast milk, 220

Nitrazepam, in geriatric patients, 597  
 Nitrofurantoin, levels in breast milk, 211; pneumonitis, 654  
 Nitroglycerin, diagnostic value in ischemic heart disease (ab) 125  
 Nitroprusside, IV use, 30  
 Nomograms, theophylline, IV (ab) 700; dosing (letter) 426  
 Noncompliance See Patient Compliance  
 Norethindrone, solubility, 418  
 Norethisterone, kinetics and metabolism (ab) 184  
 Nortriptyline, levels in breast milk, 215; pharmacokinetics from IV data (ab) 700  
 Novobiocin, levels in breast milk, 212  
 Nurses' Practice, administration of blood products (ab) 183  
 Nurse Specialist, in family planning (ab) 121  
 Nutrition See Foods, Parenteral Nutrition

## O

O'Connor, Wayne M., (author) letter, pharmacy administration as a level of pharmacy practice, 243  
 Odera, Gary M. (ed) The Pharmacist - Dedicated to the Prevention of Drug Toxicity? 176  
 Office Practice Concept, 100  
 Ogzewalla, C. Dwayne (author) book review, 499  
 Oncologic Agents, See Cancer Therapy, Cytotoxic Agents  
 Oral Contraceptives, See Contraceptives, Oral  
 Osterberger, David J. (author) letter, pharmacy revolution needed, 58  
 Otitis Media, acute, 665  
 Otolotoxic Drugs, 663; (ab) 61, (ab) 443  
 Ototoxicity, amikacin (ab) 61, (ab) 443; 663  
 Otten, Nick (author) drug evaluation data, 604  
 Overdose, See Adverse Drug Reactions  
 Oxacillin, dialysis, 410; induced agranulocytosis, 420; IV use, 30  
 Oxprenolol, pharmacokinetics (ab) 124  
 Oxygen, for pressure sores, 163  
 Oxypentoxazone, levels in breast milk, 213  
 Oxytocin, intravenous, infusion (letter) 243, use, 30; levels in breast milk, 219

## P

Package Inserts, inconsistencies in (letter) 751  
 Packaging, of IV solutions, 354  
 Paiva, Kenneth B. (author) letter, Dr. Clinical: too much flatus? 244  
 Papers, coauthorship criteria (letter) 558  
 Parascandola, John L. (author) Diet and Die with Excess Alpha Dinitrophenol, 488  
 Parenteral Nutrition, fatty acid deficiency (ab) 62; infants and children (ab) 63; intravenous fat emulsion for pressure sores, 165; level of trace elements, 465; sideroblastic anemia, inadequate copper replacement, 536; total nutrition protocol, 714  
 Parenteral Solutions, See also Intravenous, Parenteral Nutrition, diazepam, infusion (letter) 491, safety of questioned (letter) 690; fluid & electrolyte therapy, 549; furosemide, interaction from IV use, 443; guidelines for hospitals and manufacturers, 345; incompatibilities in large volume, 345; infusion, amphotericin B (letter) 368, oxytocin (letter) 243; phenytoin crystallization, 646; precipitation of solubilized drugs, 417; role of the nurse, pharmacist and the physician (ed) 366; thrombophlebitis with IV anticancer drugs, 267  
 Parenteral Therapy, utilization review, 549  
 Pathophysiology, acute otitis media, 666  
 Patient Compliance, acute otitis media drug therapy, 669; determination of, 83; drug labeling relationships, 362; effects of pharmacist consultation on (letter) 749; improvement in, 621; Mediset<sup>TM</sup>-induced overcompliance (letter) 687; noncompliance due to minocycline reactions, 26; use of mini-charts, 92  
 Patient Counseling, See also Monitoring Drug Action, by health practitioners (ed) 490; in Israel, 680; patient-pharmacist interaction, 81  
 Patient Monitoring, See also Monitoring, Patient Profiles, industry's obligation to clinical pharmacists, 740  
 Patient-Pharmacist Interaction, drug misuse, 81; effects of pharmacist consultation (letter) 749  
 Patient Profiles, mini-charts, accountability, responsiveness, 92  
 Patient Volunteer, consent (ab) 182  
 Pediatric, trace element formula, 536  
 Pemoline, adverse reaction (letter) 367  
 Penicillin G, coagulation disorder induced (ab) 123; dialysis, 410; in geriatric patients, 597, procaine, 597; IV use, 30; stability in minibags, 226, 542  
 Penicillins, dialysis, 410; levels in breast milk, 210

Pentaerythritol Tetranitrate, pharmacokinetics (ab) 632  
 Pentamidine, treatment of pneumocystis carinii pneumonia (letter) 370  
 Pentobarbital, pharmacokinetics from IV data (ab) 700  
 Pepping, Joseph (coauthor) letter, See Hull, Robert Lee, 57  
 Perrier, Donald (coauthor) See Rapp, Robert F., 462  
 Petelka, P. (coauthor) letter, See Issa, Anne, 492  
 Pevouka, M. Peter, (coauthor) Interaction of Chloral Hydrate and Furosemide: A Controlled Retrospective Study, 332  
 Phaff, Harry (coauthor) Time for Introspection, 681; (author) letter, honorary doctorate degrees, 493; (author) letter, physical assessment and the clinical pharmacist, 426  
 Pharm.D. See also Degrees, plagiarism by (letter) 180; number of degrees (ed) 177; professional degrees, 681, (letter) 108; rebuttal to universal, 477  
 Pharmaceutical Education, CE for senior pharmacists (letter) 108; cost of clinical education (ab) 627; educational films available (letter) 688; family practice, 621; goal implementation and outcome in medical schools, (ab) 247; number of degrees (ed) 177; promised land or Tower of Babel, comment on Millis Commission Report, 204  
 Pharmaceutical Industry, more clinical drug information wanted by pharmacists (letter) 493; obligation to clinical pharmacists, 740; TV advertising (ab) 496  
 Pharmaceutics, defined, 290  
 Pharmacist, and the family (letter) 305; looks at Study Commission, 94; patient interaction, drug misuse, 81; physician relationship, 616; prescriber (ed) 105; professional fees, 616; relationship with dentist in pain control (ab) 249  
 Pharmacists' Roles, aids in diagnosis (letter) 246; dispenser and prescriber, 94; effects of consultation on compliance (letter) 749; in drug therapy (ab) 120; in family practice, 616; patient counseling (ed) 490; physical assessment, 200, (letter) 623; prevention of drug toxicity (ed) 176; rebuttal to universal Pharm.D., 477  
 Pharmacokinetic and Biopharmaceutic Terminology 281; (ed) 304  
 Pharmacokinetics  
 acetaminophen (letter) 426  
 acetylsalicylic acid, from IV data (ab) 700  
 amikacin, hemodialysis and peritoneal dialysis (ab) 378  
 aminophylline, IV, 12  
 amoxicillin (ab) 378  
 ampicillin, from IV data (ab) 700  
 bumetanide (ab) 632  
 carbocillin, 484  
 cefamandole (ab) 185; hemodialysis and peritoneal dialysis (ab) 62; renal failure (ab) 62, (ab) 378  
 cefatrizine (ab) 698  
 cefazafur, compared to cephalothin and cefazolin (ab) 316  
 cefazolin, from IV data (ab) 700  
 cephalaxin, from IV data (ab) 700  
 chlorthalidone (ab) 502  
 chlorpheniramine (ab) 632  
 cimetidine, 723  
 clindamycin, from IV data (ab) 700  
 coumarin (ab) 316  
 cytosine arabinoside (ab) 564  
 defined, 290  
 dialysis of drugs, aspects of, 407  
 diazepam, from IV data (ab) 700  
 diflunisal (ab) 698  
 digitalis glycosides, 78  
 digitoxin (ab) 699  
 digoxin, from IV data (ab) 700  
 diphenhydramine, from IV data (ab) 700  
 doxycycline (ab) 633  
 drug distribution volume, implications of changes (ab) 185  
 drugs, levels in breast milk, 208  
 ergot alkaloids (ab) 633  
 fluoride, enflurane anesthesia (ab) 125  
 glyceryl trinitrate (ab) 632  
 griseofulvin, from IV data (ab) 700  
 history (ed) 747  
 hydralazine, elimination (ab) 503  
 hydroflumethiazide (ab) 502  
 industry's obligation to clinical pharmacists, 740  
 isoniazid (ab) 184  
 isosorbide dinitrate (ab) 379; (ab) 699  
 K<sup>app</sup> use in determining stability and compatibility on IVs, 350  
 kanamycin (ab) 633  
 lactulose, 604  
 norethisterone enanthate (ab) 184  
 nortriptyline, from IV data, (ab) 700  
 oxprenolol (ab) 124  
 pentaerythritol tetranitrate (ab) 632  
 pentobarbital, from IV data (ab) 700

phenprocoumon, affected by cholestyramine (ab) 753  
 phenytoin, dose calculation in digitalized patients (letter) 690; from IV data (ab) 700; products (ab) 700  
 pindolol, from IV data (ab) 700  
 pirofen (ab) 699  
 procainamide, toxicity (ab) 124  
 quercetin, from IV data (ab) 700  
 rifampicin (ab) 124  
 salicylic acid, from IV data (ab) 700  
 sex variation, 401  
 sodium valproate (ab) 564; (ab) 754  
 spectinomycin, from IV data (ab) 700  
 succinylcholine (ab) 63  
 sulfisoxazole, from IV data (ab) 700  
 terminology, progress in developing a standard, 281  
 tetracycline (ab) 633  
 theophylline, children with asthma (ab) 63; therapy, 144  
 ticarcillin, 484  
 tobramycin, from IV data (ab) 700; maternal-fetal (ab) 753  
 tranexamic acid, from IV data (ab) 700  
 trazodone (ab) 316  
 trimethoprim (ab) 124  
 warfarin, from IV data (ab) 700  
**Pharmacology**, cefadroxil compared to cephalixin, cephradine (ab) 378  
**Pharmacy**, revolution needed (letter) 58; technician issue (ed) 56  
**Pharmacy Administration**, as a level of pharmacy practice (letter) 179; (letter) 243  
**Pharmacy Practice**, administration as a level of (letter) 179, (letter) 243; family pharmacist, views Millis Report, 94, (letter) 305, 369, floor plan for practice, 616; image (ab) 121; levels (letters) 109, 557; office practice concept, 94; patient's attitude toward, 83; pharmacists' roles in, 477; promised land or Tower of Babel, comment on Millis Commission Report, 204  
**Pharmacy Technicians**, for drug dispensing (ed) 178; issue (ed) 56; revolution needed (letter) 58; use of (letter) 109  
**Phenacetin**, induced sulfhemoglobinemia (ab) 123  
**Phenindione**, levels in breast milk, 212  
**Phenobarbital**, interference, theophylline assay (ab) 753; warfarin, interaction (letter) 370  
**Phenothiazines**, dialysis, 412; in geriatric patients, 597  
**Phenprocoumon**, cholestyramine, interaction (ab) 753  
**Phenylbutazone**, interference, theophylline assay (ab) 753; levels in breast milk, 213  
**Phenylophrine**, IV use, 30  
**Phenytoin**, bioavailability (ab) 700; calculation of antiarrhythmic doses in digitalized patients (letter) 690; crystallization in IV fluids, 646; dialysis, 411, 412; diluted with aqueous tetraglycol for clinical use (ab) 632; dosing in, geriatrics, 597, infants, 462; free fraction values (ab) 442; induced systemic lupus erythematosus, 590; interference, theophylline assay (ab) 753; IV use, 30; levels in breast milk, 215; metabolism stimulated by loxapine (letter) 428; nocturnal enuresis (letter) 492; osteomalacia (ab) 185; pharmacokinetics from IV data (ab) 700; toxicity, in liver disease (letter) 57  
**Phosphate**, IV nutrient requirements, 723  
**Phosphorus**, alternated with calcium infusions, effects on osteoporosis (ab) 62  
**Physical Assessment**, and the clinical pharmacist, 200, (ed) 242, (letter) 426, encouraged (letter) 623, endorsed (letter) 623; general principles, 200; of the ear, 657; of the integumental system, 270, post-test, 723  
**Physician's Assistants**, patient's acceptance (ab) 432  
**Phytonadione**, IV use, 30  
**Pierpaoli**, Paul G. (author) book review, 692  
**Pindolol**, pharmacokinetics from IV data (ab) 700  
**Pirofen**, pharmacokinetics (ab) 699  
**Placebo**, metoclopramide compared (ab) 443; who responds to sugar pills (ab) 249  
**Plagiarism**, author (letter) 244; Pharm.D. (letter) 180  
**Platinum Complexes**, anticancer drug (ab) 699  
**Poisoning**, See also **Adverse Drug Reactions**, camphor (letter) 110  
**Polio Virus**, breastfeeding, 219  
**Potassium**, chloride IV use, 30; electrolyte therapy, 549; IV nutrient requirements, 723  
**Precipitation**, of solubilized drugs, 417  
**Prednisone**, bioavailability (ab) 252; levels in breast milk, 217  
**Prednisolone**, levels in breast milk, 216  
**Pregnancy Testing**, two hour tube test (letter) 555  
**Prescribing**, See also **Drug Prescribing**, pharmacists role, 96; the Pharmacist prescriber (ed) 105  
**Prescription Drugs**, outpatient (ab) 120  
**Pressure Sores**, drugs to treat, 154

**Primary Care**, physician management of patients (ab) 627  
**Probenecid**, effect on cefamandole serum levels (ab) 753  
**Procainamide**, adverse reaction (letter) 425; dialysis, 411; IV use, 30; toxicity, clinical, pharmacokinetic (ab) 124  
**Professional Degrees**, See **Degrees**, Pharm.D.  
**Progestogens**, levels in breast milk, 216  
**Proksch**, Richard A. (coauthor) Sex Variation and Drug Therapy, 398  
**Propoxyphene**, dialysis, 412; levels in breast milk, 213; treatment of overdose (letter) 179  
**Propranolol**, dialysis, 411; in geriatric patients, 597; IV use, 30; levels in breast milk, 219  
**Prostaglandins**, use of 15(S)-15 methyl PGF<sub>2α</sub> to induce abortion (ab) 63  
**Protein binding**, of racemic warfarin (ab) 442  
**Protein Hydrolysate**, Cutter®, trace elements, 466; solutions, 714  
**Pseudotumor Cerebri**, treatment with corticosteroids (letter) 108  
**Psychotropic Drugs**, deaths, suicide, non-suicide (ab) 121  
**Pyrimethamine**, levels in breast milk, 211

Q

**Quercetin**, pharmacokinetics from IV data (ab) 700  
**Quinidine**, dialysis, 411; IV use, 30  
**Quinine**, levels in breast milk, 211

R

**Radiation**, and chemotherapy in acute leukemia (ab) 379  
**Radiopharmaceuticals**, levels in breast milk, 217  
**Rape**, treatment of victims with diethylstilbestrol (ab) 182  
**Rapp**, Robert P. (author) book review, 629; (coauthor) Phenytoin Dosing in Infants, 462; (coauthor) See **Baars**, Ronald, 610  
**Rational Prescribing**, fluids & electrolytes, 549  
**Rault**, Raymond (coauthor) See **Swenson**, John P., 714  
**Renal Clearance**, defined, 287  
**Renal Function**, See **Kidney Function**  
**Renal Toxicity**, See **Kidney Function**  
**Reserpine**, IV use, 30; levels in breast milk, 219  
**Resman**, Beth Holly (coauthor) See **McLeod**, Don C., 736  
**Respiratory**, emergency, rapid calculations for, 610; visiting nurse respiratory rehabilitation program (ab) 183  
**Richardson**, Robert H. (coauthor) See **Hendel**, Leslie, 12  
**Rifampicin**, metabolism, with antipyrene (ab) 503, with hexobarbital (ab) 503; pharmacokinetics (ab) 124  
**Rigdon**, Don L. (coauthor) See **Grill**, Frank J., 26  
**Risk**, of medicinal interaction in long-term medical patients (ab) 497  
**Ritschel**, Gerda (author) book review, 373  
**Roark**, Richard D. (coauthor) See **Scalley**, Robert D., 420  
**Role**, of the health practitioner in patient counseling (ed) 490; physician assistants and patient acceptance (ab) 432  
**Rolitetraclazine**, stability in minibags, 226, 542  
**Romano**, Joseph A. (coauthor) letter, pregnancy testing, 555  
**Rosenzweig**, Marcel (coauthor) See **Henney**, Jane E., 266  
**Rosenthal**, Harvey L. (coauthor) letter, See **Fong**, William L., 750  
**Ruggero**, William (coauthor) letter, See **Romano**, Joseph A., 555  
**Russell**, Wayne L. (coauthor) letter, industry's interest, 493  
**Rutkowski**, Diane, (coauthor) See **Shinn**, Arthur F., 140  
**Ryan**, Gae M. (coauthor) letter, phenytoin metabolism stimulated by loxapine, 428

S

**Salicylates**, See also **Sodium Salicylate**, adult intoxication (ab) 252; blood/saliva concentration in rheumatoid arthritis (ab) 633; diflunisal and (ab) 698; interference, theophylline assay (ab) 753  
**Salicylic Acid**, pharmacokinetics from IV data (ab) 700  
**Sartori**, Hellfried E. (coauthor) letter, estrogen-induced hyperlipemia in a male, 556  
**Sather**, Mike R. (coauthor) Pressure Sores and the Spinal Cord Injury Patient, 154  
**Scalley**, Robert D. (coauthor) Oxacillin-Induced Agranulocytosis, 420  
**Schlegel**, John F. (author) letter, educational films available, 688  
**Schroeder**, Roger (coauthor) See **Cornell**, Joseph A., 180  
**Schultz's Disease**, 420  
**Schweigert**, Byron F. (author) book review, 371; (coauthor) See **Cacace**, Larry G., 22

**Scopolamine**, levels in breast milk, 213  
**Scriven**, John J., Jr. (coauthor) See **Stewart**, Ronald B., 520  
**Self-medication**, See **Patient Compliance**  
**Selle**, Robert L., Jr. (coauthor) letter, dialysis of drugs, error in article, 623  
**Sex**, linked diseases, 398; variation and drug therapy, 398  
**Shannonhouse**, William R. (coauthor) letter, See **Wood**, John H., 495  
**Sharpe**, Thomas R. (coauthor) See **Larson**, Lon N., 338  
**Shearer**, Cameron A. (coauthor) The Availability of Trace Elements in Intravenous Hyperalimentation Solutions, 465  
**Shinn**, Arthur F. (coauthor) Dosage Modifications of Cancer Chemotherapeutic Agents in Renal Failure, 140  
**Shirkey**, Harry C. (author) Clinical Pharmacy - Past, Present & Future, 664  
**Side Effects**, See **Adverse Drug Reactions**, **Agranulocytosis**, **Individual Drug Names**, **Kidney Function**, **Liver Function**, **Ototoxicity**, **Vestibular Toxicity**  
**Siepler**, John K. (coauthor) See **Bauman**, Jerry L., 646  
**Simon**, Gilbert I. (coauthor) letter, See **Romano**, Joseph A., 555  
**Simonson**, William (coauthor) Nitrofurantoin Pneumonitis, 654  
**Slama**, Philip J. (coauthor) letter, the effects of pharmacist consultation on patient compliance, 750  
**Slutsky**, Phyllis (coauthor) letter, See **Vlasses**, Peter H., 687  
**Smith**, Mickey C. (coauthor) See **Larson**, Lon N., 338  
**Smoking**, aid in stopping through hypnosis (ab) 183; and breast feeding, 220  
**Social and Economic Aspects of Drug Use**, See also **Health Care Sociology**, drug use in Australia and U.S., 298  
**Sodium**, electrolyte therapy, 549; IV nutrient requirements, 723  
**Sodium Bicarbonate**, IV use, 30  
**Sodium Chloride**, fatal ingestion of table salt (ab) 628; hypertonic, intra-amniotic injection (ab) 752  
**Sodium Oxychlorosene**, for pressure sores, 154  
**Sodium Salicylate**, See also **Salicylates**, levels in breast milk, 213  
**Sodium Valproate**, kinetics (ab) 564; pharmacokinetics and bioavailability (ab) 754  
**Solubility**, enhanced by cosolvents, 417  
**Sonnedecker**, Glenn (author) letter, levels of pharmacy practice, 557  
**Spectinomycin**, pharmacokinetics from IV data (ab) 700  
**Spironolactone**, effects of aspirin with (ab) 253; in essential hypertension (ab) 501; induced gynecomastia, 70  
**Sramek**, John J. (coauthor) letter, the family pharmacist, 369  
**Stability**, antibiotic admixtures in minibags and minibottles, 226; frozen antibiotics in minibags, 542; criteria for acceptable levels of, 345; large volume parenteral solutions, 345; phenytoin in IV solutions, 646  
**Status**, writing as a criteria (ab) 248  
**Steinberg**, Craig (author) letter, drug information bulletins, 244  
**Stennett**, Douglass J. (coauthor) See **Simonson**, William, 654  
**Steroids**, solubility, 418  
**Stewart**, Ronald B. (author) book review, 693; (coauthor) Clindamycin Associated Diarrhea - A Retrospective Study, 520; (coauthor) See **Pevonka**, M. Peter, 332; (ed) The Medicine Show Revisited, 686  
**Stimmel**, Glen L. (author) book review, 693  
**Streptokinase-Streptodornase**, for pressure sores, 154  
**Streptomycin**, dialysis, 410  
**Streptozotocin**, toxicity, adriamycin (ab) 124  
**Study Commission**, on pharmacy, practitioner's view, 94; report on pharmacy, promised land or Tower of Babel, 204  
**Succinylcholine**, kinetics (ab) 63  
**Sugar**, treatment for dehydration, 154  
**Sulfamethoxazole and Trimethoprim**, dialysis, 411; treatment of pneumocystis carinii pneumonia (letter) 370  
**Sulfasalazine**, effect on digoxin bioavailability (ab) 253  
**Sulfisoxazole**, pharmacokinetics from IV data (ab) 700  
**Sulfonamides**, levels in breast milk, 210  
**Sulfonurea Agents**, dialysis, 413  
**Superstition**, Edward (author) letter, levels of pharmacy practice, 109; (coauthor) See **Yoselson**, Shimon, 678  
**Sutlains**, for pressure sores, 154  
**Swenson**, John P. (author) letter, small-volume unit dose packaging, 109; (coauthor) A Total Parenteral Nutrition Protocol, 714  
**Syringe devices**, for visually impaired diabetics (letter) 623  
**Systemic Lupus Erythematosus**, drug-induced, 590

# T

- Tagamet®, drug evaluation data, 723
- Tan, Jeanne (coauthor) letter, See Daoud, David, 491
- Tannenbaum, Renee P. (coauthor) See LaFrancia, Margherita, 477
- Tartrazine, drugs containing (letter) 180, 492
- Taylor, Elmer, Jr. (coauthor) letter See Vlasses, Peter H., 687
- Taylor, G. R. (author) letter, Dr. Clinical's insight, 60
- Technicians, comments on Millis Commission Report, 205
- Tehrani, Jamshid B. (coauthor) letter, IV diazepam in tetanus treatment, 491
- Terbutaline, beta-2 agonists, 526
- Test, physical assessment of the integumental system, 743
- Tetracyclines, associated hemorrhages, onycholysis (ab) 123; dialysis, 410; in geriatric patients, 597; IV use, 30; levels in breast milk, 210; malprescribing of liquid preparations (ab) 694; milk inactivation of (letter) 495; pharmacokinetics (ab) 633; resistance in pneumococci & streptococci (ab) 316
- Tetraglycol, aqueous diluent for clinical use of phenytoin (ab) 632
- Theophylline, assay, drug interference (ab) 753; dosage calculation (letter) 426; dyphylline bronchodilator (ed) 424; IV nomogram guidelines (ab) 700; kinetics in children with asthma (ab) 63; rational therapy, review, 144, addendum to (letter) 305, comments on (letter) 369, article questioned (letter) 624, author's reply (letter), 494; volume of distribution in therapy (letter) 494
- Therapy, acute otitis media, 665; cancer, cytotoxic drugs (ab) 444; for metastatic breast cancer (ab) 185
- Thiamine, interference, theophylline assay (ab) 753
- Thiazide Diuretics, in geriatric patients, 597
- Thiopental Sodium, levels in breast milk, 215
- Thioridazine, in geriatric patients, 597
- Thiourea, levels in breast milk, 217
- Thompson, Gregory A. (coauthor) letter, See Devine, Ben J., 626
- Thyroxine, levels in breast milk, 217
- Ticarcillin, and carbenicillin, evaluation, 482
- Tobramycin, dialysis, 410; in geriatric patients, 597; maternal-fetal pharmacology (ab) 753; pharmacokinetics from IV data (ab) 700
- Tognoni, G. (author) letter, symposium on evaluation of drugs, 181
- Tolamide, antihypertensive effects (ab) 443
- Tolbutamide, levels in breast milk, 217
- Tomlin, David E. (coauthor) See Phaff, Harry, 681
- Topical Antibiotics, for pressure sores, 154
- Tornatore, Frank L. (coauthor) letter, See Sramek, John J., Jr., 369
- Toxicity, See also Adverse Drug Reactions, Agranulocytosis, Individual Drug Names, Kidney Function, Liver Function, Ototoxicity, Vestibular Toxicity, treatment of, dialysis of drugs, 407
- Trace Elements, deficiencies in total parenteral nutrition, 536; in Travasol® injections (letter) 690
- Tranexamic Acid, pharmacokinetics from IV data (ab) 700
- Transcendental Meditation, relief of anxiety (ab) 182
- Trazodone, kinetics and metabolism kinetics (ab) 316
- Triazolam, solubility, 417
- Triboletti, Mary, (coauthor) See Katz, Seymour, 740
- Tricyclic Antidepressants, levels in breast milk, 215; plasma levels after overdose (ab) 314
- Trimethaphan, IV use, 30
- Trimethoprim, levels in breast milk, 212; pharmacokinetics (ab) 124; and sulfamethoxazole, dialysis, 411; treatment of pneumocystis carinii pneumonia (letter) 370
- Trinca, Carl E. (author) letter, southwestern clinical pharmacy seminar, 59
- Trypsin, for pressure sores alone, 163, in combination with chymotrypsin and neomycin, 154

# U

- Uden, Donald L. (coauthor) See Lundin, Sharon R., 278
- Unit Dose Packaging, small volume (letter) 109

# V

- Valvani, S. C. (coauthor) See Yalkowsky, S. H., 417
- Vancomycin, dialysis, 411
- VanDer Linde, Larry P. (coauthor) Guidelines for the Intravenous Administration of Drugs, 30, comments on article (letters) 243, 305, 368, author's reply (letter) 306, corrections to article (letters) 306, 307, request for reprints (letter) 243
- Vasodilator Therapy, in congestive heart failure

- (ab) 254; in geriatric patients, 597
- Varano, Carmine (author) letter, camphor poisoning, 110
- Venditti, Salvatore M. (author) letter, warfarin and phenobarbital interaction, 370
- Vestibular Toxicity, minocycline, 26, (ab) 62, (ab) 503
- Vitamin A, and oral zinc in acne (ab) 317
- Vitamin B, IV use, 30
- Vitamin C, See Ascorbic Acid
- Vitamins, dialysis, 413; levels in breast milk, 217; use with protein hydrolysates, 714
- Vlasses, Peter H. (coauthor) letter, Mediset™ induced overcompliance, 687
- Volume of Distribution, defined, 288
- Von Hoff, Daniel D. (coauthor) See Henney, Jane E., 266

# W

- Wagner, John G. (ed) History of Pharmacokinetics, 747
- Wallace, Diane E. (coauthor) Drug Effects in Geriatric Patients, 597
- Wanke, Lee A. (author) letter, self-instructional guide to the Iowa Drug Information Service, 689
- Wareham, Darryl V. (coauthor) Rational Fluid and Electrolyte Therapy Utilization Review, Part II, 549
- Warfarin, free fraction values (ab) 442, in breast milk (ab) 694; in geriatric patients, 597; pharmacokinetics from IV data (ab) 700; phenobarbital, interaction (letter) 370
- Watanabe, Arthur S. (author) Pharmacokinetic Aspects of the Dialysis of Drugs, 407, comment on article (letter) 623, editor's correction to article, 623; (coauthor) See Wallace, Diane E., 597
- Weber, Charles E., Jr. (author) letter, guidelines for the IV administration of drugs, 306; (coauthor) See Sather, Mike R., 154
- Weinberger, Miles (ed) See Hendele, Leslie, 424; (author) letter, "rational theophylline therapy" article contents questioned, 624
- Whitby, J. L. (coauthor) See Dinell, B. A., 226; (coauthor) See Dinell, B. A., 542
- White, Eugene V. (author) A Family Pharmacist Takes a Critical Look at the Study Commission on Pharmacy, 94, comment on article (letters) 305, 369
- Whitney, Harvey A.K., Jr. (ed) Standards of Practice, 554; (ed) The Pharmacy Technician, Issue, 56
- Wilner, Freeman M. (coauthor) See Shinn, Arthur F., 140
- Wilson, Steve (author) letter, IV Guidelines, 306
- Winek, Charles L. (author) book review, 499
- Women, susceptibility of athletes to injury (ab) 249
- Wong, Pamela O. (coauthor) letter, See Fong, William L., 750
- Wood, John H. (coauthor) letter, milk inactivation of tetracycline, 495
- Woodworth, David A. (author) letter, northwest management seminar, 244
- World Health Organization (author) book review, 630
- Worldwide Regulatory Requirements, 470
- Writing, as a test of status (ab) 248

# X-Y-Z

- Xanthine Derivatives, interference, theophylline assay (ab) 753
- Yalkowsky, S. H. (coauthor) Precipitation of Solubilized Drugs Due to Injection or Dilution, 417
- Yosselson, Shimon (coauthor) Drug Utilization Patterns in Israel, 678
- Yost, Richard L. (coauthor) See Pevonka, M. Peter, 332
- Young, Byron (coauthor) See Rapp, Robert P., 462
- Zarek, John E. (author) Uncontrollable Seizures in an Epileptic, 590
- Zathurecky, Ladislav (author) Progress in Developing a Standard Terminology in Biopharmaceutics and Pharmacokinetics, 281
- Zinc, and vitamin A in acne (ab) 317; for pressure sores, 165; in hyperalimentation solutions, 466
- Zost, Edward D. (author) letter, TSHP annual seminar, 495

# ADVERTISERS

- American Pharmaceutical Association  
Evaluations of Drug Interactions, F-67; S-515
- American Society of Hospital Pharmacists  
International Pharmaceutical Abstracts, F-91; Mr-132; S-534
- Arizona Biomedical Information  
Phantom Notes Precip, Ap-obc
- Burroughs Wellcome Company  
Septra®, Ja-8-10; O-580-582; D-708-710
- Paul de Haen, Incorporated  
Drug Interactions, S-566; Drugs In Use, O-614; Adverse Reaction Index, N-651

- Drug Intelligence & Clinical Pharmacy, Inc.  
Subscription Information, Ja-1fc; F-1fc; Mr-1bc; Ma-1bc; JI-448; Ag-487; S-568, 1bc; O-1fc; N-673, 704; D-1bc

# Drug Intelligence Publications, Inc.

- Audio tapes, F-118-119; Ap-198-199; Ma-308-309; Ju-324-325; Ag-512, 1bc; Fluids & Electrolytes, Ag-479; Pediatric Considerations, Ju-376
- Biopharmaceutic and Pharmacokinetic Books,  
Ma-297; Ju-329; JI-393; Ag-456; O-636; N-685
- Biopharmaceutics & Relevant Pharmacokinetics, F-113
- Clinical Pharmacy Handbook for Patient Counseling, Ja-6; F-102; JI-397; S-525; N-695
- Clinical Pharmacy Practice Books, Ma-312; Ju-330; JI-391; Ag-454; S-560; O-634; N-683; D-711
- Diccionario de Especialidades Farmaceuticas, Ja-7; F-90; S-535; O-609
- Drug Consultation Guide, Ja-11; F-1fc; Mr-1fc; Ap-1fc; Ma-1fc; Ju-1fc; JI-1fc; Ag-1fc; S-1fc; O-615; N-672; D-1fc
- Drug Information & Social Pharmacy Publications, Ma-313; Ju-331; JI-392; Ag-455; S-562; O-635; N-684
- Drug Interaction Chart, N-691; D-707
- Drugs, Chemicals and Blood Dyscrasias, Ja-20-21; F-74-75; Mr-186-187; Ap-240-241; Ma-268-269; Ju-336-337; JI-394-395; Ag-480-481
- Fundamentals of Clinical Pharmacokinetics, F-68-69
- Fundamentals of Medications, S-535; O-609
- Guide to Drug Information, Ja-6; F-102; JI-390; Ag-508; S-524; O-588
- Handbook of Clinical Drug Data, Ja-6; Ma-319
- Handbook of Drug Interactions, Ja-7; F-90; S-535; O-609
- Handbook of the Pharmacology of Emergency Drugs for Paramedics, JI-387; Ag-451; S-573; O-579; N-703; D-722
- IMPRESX, F-117; Mr-190; Ap-239; Ma-265; Ju-344; JI-396; Ag-505; S-574; O-589; N-701; D-758
- Index Nominum, Ja-7; F-90; N-697; D-746
- Martindale's The Extra Pharmacopoeia, S-567; O-1bc; N-1bc; D-721
- Medisc™, F-126; Mr-190; Ap-207; Ma-265; Ju-344; JI-396; Ag-505; S-574; O-589
- MEDISSET™, F-114-115; Mr-188-189; Ap-250-251; Ma-310-311; Ju-374-375; Ag-510-511
- Perspectives in Clinical Pharmacy, S-575
- Perspectives on Medicines in Society, Ja-29; F-103; Ju-1bc; JI-1bc; Ag-457; S-576; O-583; N-643; D-727
- Pharmacokinetic Slide Rule, Ja-4; F-104; Mr-133; Ap-225; Ma-259; Ju-323; S-533; O-595; N-664
- Principles of Clinical Pharmacy Illustrated by Clinical Case Studies, Ja-6; F-102; S-572
- Social and Economic Aspects of Drug Utilization Research, Ja-5; F-122; Mr-131; Ap-224; Ju-361; JI-445; Ag-509; S-571; O-596; N-652
- The Fate of Drugs in the Organism, Ja-7; F-90; S-535; O-609
- USAN 1976 & USP Dictionary of Drug Names, F-110; Mr-169; Ap-254; Ma-280; Ju-380; JI-429
- Edith Cantor  
Drug Research, Ja-60; F-112; Mr-181; Ap-246
- Eli Lilly & Company  
Darvocet®-N, Mr-obc, Ap-1bc; Dista Products Company, Ma-obc; "Get to Know Your Pharmacist," O-1bc, N-obc, D-obc; The one the patient takes, JI-obc, Ag-obc, S-obc; V-Cillin K®, Ja-obc, F-obc; "What Does Lilly Do for Pharmacists?", Ju-obc
- Facts and Comparisons, Ma-317, D-755
- Mercy Hospital  
New Pharmacy Procedure Manual, S-569, O-637, N-653
- Personnel Placement, Ja-64; F-127; Mr-191; Ap-255; Ma-318-319; Ju-381; JI-446-448; Ag-506-507; S-566; O-639; N-702
- Publishing Sciences Group, Inc.  
AMA Drug Evaluations, Ja-19
- Roche Laboratories  
Hospital Pharmacy, Grants, Ap-196-197; Ma-260-261; Ju-382-383; Sounding Board, JI-388-389; Ag-452-453; S-518-519; The Winners, O-586-587; Your Roche Representative, Ma-262-264; Ju-326-328
- Smith, Kline & French Laboratories  
A Human Resource, F-116; Ma-1bc; S-570; N-650; Tagamet®, S-516-517; O-584-585; N-644-645
- Travenol Laboratories, Incorporated  
The Viaflex® IV System, Ap-insert between 224-225; S-insert between 544-545

